var title_f24_52_25408="Miliary infiltrates in histo";
var content_f24_52_25408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miliary infiltrates in disseminated histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph with a miliary pattern in a patient with fever, weight loss, and a bone marrow positive for granulomas and organisms resembling H. capsulatum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25408=[""].join("\n");
var outline_f24_52_25408=null;
var title_f24_52_25409="Azithromycin: Patient drug information";
var content_f24_52_25409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azithromycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=see_link\">",
"       Azithromycin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=see_link\">",
"       Azithromycin (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11117 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25409=[""].join("\n");
var outline_f24_52_25409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=related_link\">",
"      Azithromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=related_link\">",
"      Azithromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_52_25410="Brugia malayi smear";
var content_f24_52_25410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Brugia malayi smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Microfilaria of",
"    <em>",
"     B. malayi",
"    </em>",
"    in a thick blood smear, stained with Giemsa. The organism has a sheath (yellow arrow) and two nuclei in its tail (red arrows); body nuclei are dense.",
"    <br>",
"     (B) Microfilaria of",
"     <em>",
"      B. malayi",
"     </em>",
"     in a thin blood smear, stained with Giemsa.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"      <a href=\"file://dpd.cdc.gov/dpdx/html/Filariasis.htm\" target=\"_blank\">",
"       file://dpd.cdc.gov/dpdx/html/Filariasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25410=[""].join("\n");
var outline_f24_52_25410=null;
var title_f24_52_25411="Ammonium chloride: Drug information";
var content_f24_52_25411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ammonium chloride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/1/17427?source=see_link\">",
"    see \"Ammonium chloride: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metabolic alkalosis: The following equations represent different methods of correction utilizing either the serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     , the serum chloride, or the base excess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing of mEq NH",
"     </b>",
"     <sub>",
"      4",
"     </sub>",
"     <b>",
"      Cl via the chloride-deficit method (hypochloremia):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose of mEq NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = [0.2 L/kg x body weight (kg)] x [103 - observed serum chloride]; administer 50% of dose over 12 hours, then re-evaluate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     0.2 L/kg is the estimated chloride volume of distribution and 103 is the average normal serum chloride concentration (mEq/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing of mEq NH",
"     </b>",
"     <sub>",
"      4",
"     </sub>",
"     <b>",
"      Cl via the bicarbonate-excess method (refractory hypochloremic metabolic alkalosis):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose of NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = [0.5 L/kg x body weight (kg)] x (observed serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     - 24); administer 50% of dose over 12 hours, then re-evaluate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     0.5 L/kg is the estimated bicarbonate volume of distribution and 24 is the average normal serum bicarbonate concentration (mEq/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     These equations will yield different requirements of ammonium chloride",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/1/17427?source=see_link\">",
"      see \"Ammonium chloride: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Metabolic alkalosis: Refer to adult dosing for weight-based equations.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe impairment: use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe impairment:  use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: Ammonium 5 mEq/mL and chloride 5 mEq/mL (20 mL) [equivalent to ammonium chloride 267.5 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by slow intravenous infusion to avoid local irritation and adverse effects. Rate of infusion should not exceed 5 mL/minute in an adult.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in D",
"     <sub>",
"      5",
"     </sub>",
"     W, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Variable (consult detailed reference):",
"     </b>",
"     Warfarin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypochloremic states or metabolic alkalosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, drowsiness, EEG abnormalities, headache, mental confusion, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Calcium-deficient tetany, hyperchloremia, hypokalemia, metabolic acidosis, potassium may be decreased, sodium may be decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, gastric irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ammonia may be increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at site of injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hyperventilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hepatic or renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ammonia toxicity: Monitor closely for signs and symptoms of ammonia toxicity, including diaphoresis, altered breathing, bradycardia, arrhythmias, retching, twitching, and coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with primary respiratory acidosis or pulmonary insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Ammonium Chloride may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Ammonium Chloride may increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Ammonium Chloride may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ammonium Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mEq/mL (20 mL): $5.29",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum bicarbonate; signs and symptoms of ammonia toxicity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases acidity by increasing free hydrogen ion concentration",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms urea and hydrochloric acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Martin WJ and Matzke GR, &ldquo;Treating Severe Metabolic Alkalosis,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1982, 1(1):42-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25411/abstract-text/6764161/pubmed\" id=\"6764161\" target=\"_blank\">",
"        6764161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Megarbane B, Bruneel F, Bedos JP, et al, &ldquo;Ammonium Chloride Poisoning: A Misunderstood Cause of Metabolic Acidosis With Normal Anion Gap,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2000, 26(12):1869.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25411/abstract-text/11271099/pubmed\" id=\"11271099\" target=\"_blank\">",
"        11271099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8631 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25411=[""].join("\n");
var outline_f24_52_25411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134229\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134219\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134226\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134220\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673141\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673142\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134205\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134192\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134207\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134234\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134206\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134227\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134210\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134196\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298740\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217901\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134202\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134212\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322984\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134203\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134195\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134209\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/1/17427?source=related_link\">",
"      Ammonium chloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_52_25412="Uterine broad ligament";
var content_f24_52_25412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 633px\">",
"   <div class=\"ttl\">",
"    Uterine broad ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 613px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lower abdomen and pelvis of a female. Posterior view of the female internal genitalia: uterus, ovaries, uterine tubes, and related structures. The broad ligament is removed on the left side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF II. Clinical Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25412=[""].join("\n");
var outline_f24_52_25412=null;
var title_f24_52_25413="Chlorpheniramine: Pediatric drug information";
var content_f24_52_25413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"    see \"Chlorpheniramine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/16/37124?source=see_link\">",
"    see \"Chlorpheniramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aller-chlor&reg; [OTC];",
"     </li>",
"     <li>",
"      Allergy Relief [OTC];",
"     </li>",
"     <li>",
"      Chlor Hist [OTC];",
"     </li>",
"     <li>",
"      Chlor-Trimeton&reg; Allergy [OTC];",
"     </li>",
"     <li>",
"      Chlorphen [OTC];",
"     </li>",
"     <li>",
"      Chlorphen-12&trade; [OTC];",
"     </li>",
"     <li>",
"      ED Chlorped Jr [OTC];",
"     </li>",
"     <li>",
"      Ed ChlorPed [OTC];",
"     </li>",
"     <li>",
"      Ed-Chlortan [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlor-Tripolon&reg;;",
"     </li>",
"     <li>",
"      Novo-Pheniram",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"      see \"Chlorpheniramine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlorpheniramine maleate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years: 0.35 mg/kg/day in divided doses every 4-6 hours or as an alternative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years: 1 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-11 years: 2 mg every 4-6 hours, not to exceed 12 mg/day or timed release 8 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 4 mg every 4-6 hours, not to exceed 24 mg/day or timed release 8-12 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlorpheniramine tannate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2 to &lt;6 years: 2 mg (1.25 mL) twice daily; not to exceed 8 mg (5 mL) in a 24-hour period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6 to &lt;12 years: 4-8 mg (2.5-5 mL) twice daily; not to exceed 16 mg (10mL) in a 24-hour period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 8-16 mg (5-10 mL) twice daily; not to exceed 32 mg (20 mL) in a 24-hour period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dexchlorpheniramine maleate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-5 years: 0.5 mg every 4-6 hours, not to exceed 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years: 1 mg every 4-6 hours, not to exceed 6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 2 mg every 4-6 hours; not to exceed 12 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as maleate [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed ChlorPed: 2 mg/mL (60 mL) [contains propylene glycol, sodium benzoate; cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as maleate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aller-chlor&reg;: 2 mg/5 mL (118 mL) [contains ethanol 5%, menthol, propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ED Chlorped Jr: 2 mg/5 mL (473 mL) [ethanol free, sugar free; contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aller-chlor&reg;: 4 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allergy Relief: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlor Hist: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlor-Trimeton&reg; Allergy: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorphen: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ed-Chlortan: 4 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as maleate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorphen-12&trade;: 12 mg [contains calcium 28 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI distress; do not crush or chew timed release tablets; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Chlor-Trimeton&reg; may be confused with Chloromycetin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, excitability, fatigue, headache, nervousness, slight to moderate drowsiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, increased appetite, nausea, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, thickening of bronchial secretions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpheniramine maleate or any component; narrow-angle glaucoma, bladder neck obstruction, symptomatic prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with asthma; young children may be more susceptible to side effects and CNS stimulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5204859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient. Children may be at increased risk for developing CNS stimulation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal chlorpheniramine use has generally not resulted in an increased risk of birth defects. Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the GI tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     (Data from chlorpheniramine maleate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 3.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-3.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 69% to 72%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Substantial metabolism in GI mucosa and on first pass through liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Chlorpheniramine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: 35% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 25% to 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Average: 9.6-13.1 hours (range: 5.2-23.1 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 12-43 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral (solution and conventional tablets): 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 35% excreted in 48 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/16/37124?source=see_link\">",
"      see \"Chlorpheniramine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13149 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25413=[""].join("\n");
var outline_f24_52_25413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149979\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149980\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057281\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057276\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149966\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149953\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057285\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057284\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149998\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149997\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057289\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057275\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5204859\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149991\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149961\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630927\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057274\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057287\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057288\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057280\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13149|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=related_link\">",
"      Chlorpheniramine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/16/37124?source=related_link\">",
"      Chlorpheniramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_52_25414="Treprostinil: Drug information";
var content_f24_52_25414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Treprostinil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/48/14085?source=see_link\">",
"    see \"Treprostinil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Remodulin&reg;;",
"     </li>",
"     <li>",
"      Tyvaso&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3000889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Remodulin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Prostacyclin;",
"     </li>",
"     <li>",
"      Prostaglandin;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pulmonary arterial hypertension (PAH):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil and care for the inhalation system and accessories required for administration. Immediate access to a back-up inhalation device, accessories, and medication is essential to prevent treatment interruptions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 18 mcg (or 3 inhalations) every 4 hours 4 times/day; if 3 inhalations are not tolerated, reduce to 1-2 inhalations, then increase to 3 inhalations as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: If tolerated, increase dose by an additional 3 inhalations at approximately 1- to 2-week intervals; target dose and maximum dose: 54 mcg (or 9 inhalations) 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ (preferred) or I.V. infusion:",
"     <b>",
"      Note:",
"     </b>",
"     Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil and care for the infusion system outside of inpatient setting. Immediate access to a back-up pump, infusion sets, and medication is essential to prevent treatment interruptions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      New to prostacyclin therapy:",
"     </i>",
"     Initial: 1.25 ng/kg/minute; if dose cannot be tolerated due to systemic effects, reduce to 0.625 ng/kg/minute. Increase dose in increments of 1.25 ng/kg/minute per week for first 4 weeks, followed by increments of 2.5 ng/kg/minute per week for remainder of therapy. Limited experience with doses &gt;40 ng/kg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     Dose must be carefully and individually titrated (symptom improvement with minimal adverse effects). Avoid abrupt withdrawal. If infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require retitration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Transitioning from epoprostenol (see table):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Transition should occur in a hospital setting to follow response (eg, walking distance, sign/symptoms of disease progression). May take 24-48 hours to transition. Transition is accomplished by initiating the infusion of treprostinil, and increasing it while simultaneously reducing the dose of intravenous epoprostenol. During transition, increases in PAH symptoms should be first treated with an increase in treprostinil dose. Occurrence of prostacyclin associated side effects should be treated by decreasing the dose of epoprostenol.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Transitioning From I.V. Epoprostenol to SubQ (Preferred) or I.V. Treprostinil",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         Step",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         Epoprostenol Dose",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         Treprostinil Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain current dose",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Initiate at 10% initial epoprostenol dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease to 80% initial dose",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Increase to 30% initial epoprostenol dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease to 60% initial dose",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Increase to 50% initial epoprostenol dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease to 40% initial dose",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Increase to 70% initial epoprostenol dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease to 20% initial dose",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Increase to 90% initial epoprostenol dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease to 5% initial dose",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Increase to 110% initial epoprostenol dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue epoprostenol",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain current dose plus additional 5% to 10% as needed",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F230374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ; I.V. infusion: Limited experience in patients &le;16 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Limited experience in patients &ge;65 years; use caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F230366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Titrate slowly in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F230367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate: Use with caution and titrate slowly in patients with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ; I.V. infusion: Initial: 0.625 ng/kg/minute (ideal body weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe: Has not been studied in patients with severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remodulin&reg;: 1 mg/mL (20 mL); 2.5 mg/mL (20 mL); 5 mg/mL (20 mL) [contains sodium chloride 5.3 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remodulin&reg;: 10 mg/mL (20 mL) [contains sodium chloride 4 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tyvaso&trade;: 0.6 mg/mL (2.9 mL) [delivers ~6 mcg/inhalation]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Regardless of administration route (inhalation, I.V., or SubQ), treatment interruptions or rapid large dosage reductions should be avoided. Immediate access to medication, a back-up inhalation device, or pump and infusion sets is essential to prevent treatment interruptions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Do not mix with other medications. For inhalation only via the Tyvaso&trade; Inhalation System; consists of the Optineb-ir Model ON-100/7 (an ultrasonic, pulsed-delivery device) and accessories. Prior to the first treatment session of each day, transfer the entire contents of one ampule into the medicine chamber; one ampule contains sufficient volume of medication for all 4 treatment sessions in a single day. Between each session, the device should be capped and stored upright with the remaining medication inside. At the end of each day, the medicine chamber and any remaining medication must be discarded. Avoid contact of solution with eyes or skin; wash hands after handling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion: I.V. use is recommended when SubQ infusion is not tolerated or when the benefit outweighs the potential risks of an indwelling central venous catheter. Solution must be diluted in SWFI, NS, or Flolan&reg; sterile diluent prior to use and administered by continuous infusion using a central indwelling catheter and infusion pump. The ambulatory infusion pump should be small and lightweight; have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have &plusmn; 6% accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Peripheral infusion may be used temporarily until central line is established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ infusion (preferred): Administer undiluted via continuous SubQ infusion using an appropriately-designed infusion pump. The ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates in ~0.002 mL/hour increments; have occlusion/no delivery, low battery, programming error, and motor malfunction alarms; have &plusmn; 6% accuracy of the programmed rate; and be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene, or glass. Infusion site reactions may be helped by moving the infusion site every 3 days, local application of topical hot and cold packs, topical or oral analgesics. Injection site pain and erythema may improve after several months of treprostinil therapy.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5935330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in SWFI, NS, or Flolan&reg; sterile diluent;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Injection: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class II-IV symptoms to decrease exercise-associated symptoms; to diminish clinical deterioration when transitioning from epoprostenol (I.V.)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Inhalation: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III symptoms to improve exercise ability.",
"     <b>",
"      Note:",
"     </b>",
"     Nearly all controlled clinical trial experience has been with concomitant bosentan or sildenafil.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (11%; inhalation: 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (27% to 41%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (25%), nausea (19% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infusion site pain (SubQ: 85%; may improve after several months of therapy), infusion site reaction (SubQ: 83%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Jaw pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (inhalation: 54%), throat irritation/pharyngolaryngeal pain (inhalation: 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (9%), syncope (inhalation: 6%), hypotension (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (inhalation), hemoptysis, pneumonia, wheezing (inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anxiety, arm swelling, bone pain, cellulitis, central venous catheter-related line infections, central venous catheter-related sepsis, hematoma, pain, paresthesia, restlessness, thrombocytopenia, thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the FDA-approved labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May produce symptomatic hypotension; use with caution in patients with low systemic arterial blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rebound pulmonary hypertension: Abrupt withdrawal/large dosage reductions may worsen symptoms of PAH. If a SubQ or I.V. infusion is restarted within a few hours of discontinuation, the same dose rate may be used. Interruptions for longer periods may require retitration. Regardless of administration route (inhalation, I.V., SubQ), treatment interruptions should be avoided. Immediate access to medication, back-up inhalation device, or pump and infusion sets is essential to prevent treatment interruptions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dose reduction is recommended for the initial dose (I.V., SubQ) in patients with mild-to-moderate hepatic insufficiency; titrate dose slowly in patients with hepatic insufficiency; has not been studied in severe hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Has not been studied in renal impairment; use with caution in patients with renal impairment. Titrate dose slowly in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Inhalation: Safety and efficacy have not been established in patients with underlying pulmonary disease (eg, asthma, COPD). Patients with acute pulmonary infections should be monitored closely for exacerbation or reduced efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;65 years of age; clinical trial experience in this population is limited.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants/antiplatelet therapy: Treprostinil inhibits platelet aggregation, increasing the risk of bleeding; use with caution in patients receiving concurrent anticoagulant/antiplatelet therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Chronic continuous I.V. infusion of treprostinil via a chronic indwelling central venous catheter has been associated with serious blood stream infections. This method of administration should be reserved for patients who are intolerant of the SubQ route or in whom the benefit outweighs the potential risks. Clinicians should routinely review with patient the importance of infection control practices for the management of a central venous catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Treprostinil should only be used by clinicians experienced in the treatment of PAH. Prior to initiation, patients should be carefully evaluated for ability to administer treprostinil, either as an I.V./SubQ infusion or inhalation, and care for the infusion system/inhalation device. Initiation of infusion must occur in a setting where adequate personnel and equipment necessary for hemodynamic monitoring and emergency treatment are available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Prostacyclin Analogues may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Treprostinil may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Treprostinil may enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some skeletal malformations and maternal toxicity noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Use with caution and only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Remodulin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (20 mL): $1474.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg/mL (20 mL): $3685.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (20 mL): $7370.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (20 mL): $14740.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tyvaso Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/mL (2.9 mL): $554.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tyvaso Refill Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/mL (2.9 mL): $554.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tyvaso Starter Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/mL (2.9 mL): $617.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F230341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BP, dyspnea, fatigue, activity tolerance, symptoms of excessive dose (eg, headache, nausea, vomiting)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Remodulin (AR, AT, AU, BE, CH, CN, CZ, DE, DK, EE, FI, FR, GR, IL, IT, NL, NO, PT, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treprostinil is a direct vasodilator of both pulmonary and systemic arterial vascular beds; also inhibits platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: Rapidly and completely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 14 L/70 kg ideal body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (primarily by CYP2C8); forms 5 inactive metabolites (HU1-HU5)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Inhalation: 64% to 72% (dose-dependent); SubQ: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (79%; 4% as unchanged drug, 64% as metabolites); feces (13%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Bloodstream Infections Among Patients Treated With Intravenous Epoprostenol or Intravenous Treprostinil for Pulmonary Arterial Hypertension - Seven Sites, United States, 2003-2006,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2007, 56(8):170-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/17332729/pubmed\" id=\"17332729\" target=\"_blank\">",
"        17332729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gildea TR, Arroliga AC, and Minai OA, &ldquo;Treatments and Strategies to Optimize the Comprehensive Management of Patients With Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       Cleve Clin J Med",
"      </i>",
"      , 2003, 70(Suppl 1):18-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gomberg-Maitland M, Tapson VF, Benza RL, et al, &ldquo;Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 172(12):1586-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/16151039/pubmed\" id=\"16151039\" target=\"_blank\">",
"        16151039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang I, Gomez-Sanchez M, Kneussl M, et al, &ldquo;Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2006, 129(6):1636-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/16778286/pubmed\" id=\"16778286\" target=\"_blank\">",
"        16778286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(17):1573&ndash;619.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/19389575/pubmed\" id=\"19389575\" target=\"_blank\">",
"        19389575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Gaine SP, Barst RJ, et al, &ldquo;Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 2003, 41(2):293-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/12548091/pubmed\" id=\"12548091\" target=\"_blank\">",
"        12548091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubenfire M, McLaughlin VV, Allen RP, et al, &ldquo;Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007,132(3):757-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25414/abstract-text/17400684/pubmed\" id=\"17400684\" target=\"_blank\">",
"        17400684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10207 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-B6EAAB5947-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25414=[""].join("\n");
var outline_f24_52_25414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230363\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000889\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230380\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230365\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230374\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062238\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230366\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230367\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230343\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230331\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230345\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5935330\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230344\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230378\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230348\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230334\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300164\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230338\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230340\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230350\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230369\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324023\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230341\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301443\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230333\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230347\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/48/14085?source=related_link\">",
"      Treprostinil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_52_25415="Zonisamide: Pediatric drug information";
var content_f24_52_25415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zonisamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"    see \"Zonisamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/25/35221?source=see_link\">",
"    see \"Zonisamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F236246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zonegran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"      see \"Zonisamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: In a review article of 20 Japanese pediatric studies, the following doses were recommended (Glauser, 2002): Initial: 1-2 mg/kg/day given in two divided doses/day; increase dose in increments of 0.5-1 mg/kg/day every 2 weeks; usual dose: 5-8 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Higher initial and maximum doses have been recommended by others (Leppik, 1999; Oommen, 1999): Initial: 2-4 mg/kg/day given in two divided doses/day; titrate dose upwards if needed every 2 weeks; usual dose: 4-8 mg/kg/day; maximum dose: 12 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infantile spasms: Several studies used a faster titration of zonisamide to control infantile spasms. Suzuki treated 11 newly diagnosed infants (mean age: &sim;6 months) with zonisamide monotherapy starting at doses of 3-5 mg/kg/day given in 2 divided doses/day; doses were increased every 4th day until seizures were controlled or a maximum dose of 10 mg/kg/day was attained; 4 of 11 patients responded at doses of 4-5 mg/kg/day (Suzuki, 1997). Yanai treated 27 newly diagnosed infantile spasm patients with zonisamide add-on or monotherapy starting at doses of 2-4 mg/kg/day given in 2 divided doses/day; doses were increased by 2-5 mg/kg every 2-4 days until seizures were controlled or a maximum of 10-20 mg/kg/day was attained; 9 of 27 patients responded at a mean effective dose of 7.8 mg/kg/day (range: 5-12.5 mg/kg/day); non-responders received doses of 8-20 mg/kg/day (mean: 10.8 mg/kg/day) (Yania, 1999). Suzuki treated 54 newly diagnosed infants (11 of which were previously reported) with zonisamide monotherapy starting at doses of 3-4 mg/kg/day given in 2 divided doses; doses were increased every 4th day until seizures were controlled or a maximum dose of 10-13 mg/kg/day was attained; 11 of 54 infants responded at a mean effective dose of 7.2 mg/kg/day (range: 4-12 mg/kg/day); the majority of infants who responded did so at a dose of 4-8 mg/kg/day and within 1-2 weeks of starting therapy (Suzuki, 2001). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adolescents &gt;16 years and Adults: Initial: 100 mg once daily; dose may be increased to 200 mg/day after 2 weeks; further increases in dose should be made in increments of 100 mg/day and only after a minimum of 2 weeks between adjustments; usual effective dose: 100-600 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     There is no evidence of increased benefit with doses &gt;400 mg/day. Steady-state serum concentrations fluctuate 27% with once daily dosing, and 14% with twice daily dosing; patients may benefit from divided doses given twice daily (Leppik, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Slower dosage titration and more frequent monitoring are recommended. Do not use if GFR &lt;50 mL/minute. Marked renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute) was associated with a 35% increase in AUC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Slower titration and frequent monitoring are indicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F236224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zonegran&reg;: 25 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F236209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152828.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152828.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May be administered without regard to meals; swallow capsule whole; do not crush, chew, or break capsule.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature 25&deg;C (77&deg;C). Protect from moisture and light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of partial seizures (FDA approved in ages &gt;16 years and adults); has been used investigationally for the treatment of generalized epilepsies including, generalized tonic-clonic seizures, absence seizures, infantile spasms, myoclonic epilepsies, and Lennox-Gastaut syndrome (Leppik, 1999; Oommen, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6790269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zonegran&reg; may be confused with SINEquan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zonisamide may be confused with lacosamide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F236271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation/irritability, anxiety, ataxia, concentration decreased, confusion, depression, difficulty in verbal expression, dizziness fatigue, headache, hyperesthesia, incoordination, insomnia, memory impairment, mental slowing, nervousness, schizophrenic/schizophreniform behavior, seizure, somnolence, speech disorders, status epilepticus, tiredness, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, diarrhea, dyspepsia, nausea, taste perversion, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Kidney stones",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough increased, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare (but important or life threatening symptoms): Agranulocytosis, allergic reaction, alopecia, amenorrhea, aplastic anemia, apnea, arthritis, atrial fibrillation, bladder calculus, bradycardia, cerebrovascular accident, cholangitis, cholecystitis, cholestatic jaundice, colitis, deafness, duodenitis, encephalopathy, fecal incontinence, gingivitis, GI ulcer, glaucoma, heart failure, hematuria, hemoptysis, hirsutism, hyper-/hypotension, hyperthermia, hypoglycemia, hyponatremia, immunodeficiency, impotence, iritis, leukopenia, lupus erythematosus, lymphadenopathy, mastitis, menorrhagia, metabolic acidosis, neuropathy, oculogyric crisis, oligohidrosis (children), pancreatitis, photophobia, pulmonary embolus, rectal hemorrhage, Stevens-Johnson syndrome, stroke, suicidal behavior/ideation, syncope, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, urinary incontinence, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zonisamide, sulfonamides, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic dysfunction; do not use in patients with GFR &lt;50 mL/minute; zonisamide may cause kidney stones (ensure patients have adequate fluid intake); zonisamide may decrease GFR and increase serum creatinine and BUN; discontinue therapy in patients who develop acute renal failure or a persistent significant increase in serum creatinine or BUN. In children, agitation, anxiety, ataxia, and behavior disorders have been reported (Kimura, 1994).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Zonisamide is a sulfonamide; although rare, severe, and life-threatening sulfonamide reactions may occur (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, aplastic anemia, agranulocytosis, other blood dyscrasias, and fulminant hepatic necrosis); discontinue zonisamide in patients with signs of hypersensitivity reaction or other serious reactions; consider discontinuation of zonisamide in any patient who develops a rash or monitor very closely; deaths due to serious rashes have been reported; rashes usually appear within 2-16 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use may be associated with the development of hyperchloremic, non-anion gap, metabolic acidosis (generally dose-dependent); predisposing conditions or therapies include renal disease, severe respiratory disease, diarrhea, surgery, ketogenic diet, and other medications (such as acetazolamide or topiramate). Pediatric patients may also be at an increased risk and may have more severe metabolic acidosis. Serum bicarbonate should be monitored prior to initiation and during therapy; if metabolic acidosis occurs, consider decreasing the dose or discontinuing use with appropriate dose tapering. If use continues despite acidosis, alkali treatment should be considered. Untreated metabolic acidosis may increase the risk of developing nephrolithiasis, nephrocalcinosis, osteomalacia (or rickets in children), or osteoporosis; pediatric patients may also have decreased growth rates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oligohydrosis (decreased sweating) and hyperthermia have been reported in 40 pediatric patients; many cases occurred after exposure to elevated environmental temperatures; some cases resulted in heat stroke requiring hospitalization; pediatric patients may be at an increased risk; monitor patients, especially pediatric patients, for decreased sweating and hyperthermia, especially in warm or hot weather; use zonisamide with caution in patients receiving drugs that predispose to heat-related disorders (eg, anticholinergic agents, carbonic anhydrase inhibitors); safety and efficacy in pediatric patients &lt;16 years of age has not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not abruptly discontinue therapy; abrupt withdrawal may precipitate seizures; withdraw gradually to lessen chance for increased seizure frequency (unless a more rapid withdrawal is required due to safety concerns). CNS adverse effects may occur including fatigue or somnolence, psychiatric symptoms (eg, depression, psychosis), and cognitive symptoms [difficulty concentrating, speech or language problems (especially word-finding difficulties), and psychomotor slowing]; fatigue and somnolence usually occur within the first month of starting therapy, most commonly at higher doses (eg, in adults at doses of 300-500 mg/day). Patients should be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F236259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F236218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the rate, but not the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F236220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F236232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies; therefore, zonisamide is classified as pregnancy category C. Zonisamide crosses the placenta and can be detected in the newborn following delivery. Although adverse fetal events have been reported, the risk of teratogenic effects following maternal use of zonisamide in not clearly defined. Other agents may be preferred until additional data is available. Newborns should be monitored for transient metabolic acidosis after birth. Zonisamide clearance may increase in the second trimester of pregnancy, requiring dosage adjustment. Women of childbearing potential are advised to use effective contraception during therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to zonisamide during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at file://www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency, duration, and severity; symptoms of CNS adverse effects; skin rash; periodic BUN and serum creatinine; serum bicarbonate prior to initiation and periodically during therapy; serum electrolytes, including chloride, phosphorus, and calcium; alkaline phosphatase; serum albumin; symptoms of metabolic acidosis; monitor patients, especially pediatric patients, for decreased sweating and hyperthermia, especially in warm or hot weather; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitoring of plasma concentrations may be useful; proposed therapeutic range: 10-20 mcg/mL; patients may benefit from higher concentrations (ie, up to 30 mcg/mL), but concentrations &gt;30 mcg/mL have been associated with adverse effects (Leppik, 1999; Oommen, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism of action is not known; may stabilize neuronal membranes and suppress neuronal hypersynchronization by blocking sodium channels and T-type calcium currents; does not affect GABA activity. Zonisamide is a carbonic anhydrase inhibitor; the contribution of this effect to its antiepileptic action is unknown; however, this effect may result in metabolic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): 1.45 L/kg; highly concentrated in erythrocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; undergoes acetylation to form N-acetyl zonisamide and reduction via cytochrome P450 isoenzyme CYP3A4 to 2-sulfamoylacetylphenol (SMAP); SMAP then undergoes conjugation with glucuronide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: ~63 hours (range: 50-68 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine: 62% (35% as unchanged drug, 15% as N-acetyl zonisamide, 50% as SMAP glucuronide); feces (3%);",
"     <b>",
"      Note:",
"     </b>",
"     Of the dose recovered in Japanese patients, 28% is as unchanged drug, 52% is as N-acetyl zonisamide, and 19% is as SMAP glucuronide (Glauser, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/25/35221?source=see_link\">",
"      see \"Zonisamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of zonisamide. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Inform prescriber if allergic to sulfa drugs (eg, Bactrim&reg;, Septra&reg;). Do not abruptly discontinue therapy (an increase in seizure activity may result). May cause drowsiness and impair ability to perform activities that require mental alertness or physical coordination. Report excessive drowsiness, unusual thoughts, depression, problems with concentrating or speaking, or any skin rashes to physician immediately. Avoid alcohol. Report fast breathing, feeling of being very tired, loss of appetite, irregular heartbeat, or palpitations to physician immediately, as these may be signs of metabolic acidosis. Notify physician immediately if a child taking zonisamide is not sweating as usual or has elevated temperature. Drink adequate amount of fluids and report any symptoms of kidney stones (eg, back pain, stomach pain, pain on urination, bloody urine). Report any unusual symptoms, such as a bruises, sore throat, fever, or mouth ulcers to physician. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions during preparation and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL suspension may be made using capsules and either simple syrup or methylcellulose 0.5%. Empty contents of ten 100 mg capsules into glass mortar. Reduce to a fine powder and add a small amount of Simple Syrup, NF and mix to a uniform paste; mix while adding the chosen vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to an amber calibrated plastic bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label \"shake well\" and \"refrigerate\". When using simple syrup vehicle, stable 28 days at room temperature or refrigerated (preferred). When using methylcellulose vehicle, stable 7 days at room temperature or 28 days refrigerated.",
"     <b>",
"      Note:",
"     </b>",
"     Although no visual evidence of microbial growth was observed, storage under refrigeration would be recommended to minimize microbial contamination.",
"    </p>",
"    <div class=\"reference\">",
"     Abobo CV, Wei B, and Liang D, \"Stability of Zonisamide in Extemporaneously Compounded Oral Suspensions,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2009, 66(12):1105-9.",
"     <span class=\"pubmed-id\">",
"      19498126",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA and Pellock JM, &ldquo;Zonisamide in Pediatric Epilepsy: Review of the Japanese Experience,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2002, 17(2):87-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/11952083/pubmed\" id=\"11952083\" target=\"_blank\">",
"        11952083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kawada K, Itoh S, Kusaka T, et al, &ldquo;Pharmacokinetics of Zonisamide in Perinatal Period,&rdquo;",
"      <i>",
"       Brain Dev",
"      </i>",
"      , 2002, 24(2):95-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/ 11891100 /pubmed\" id=\" 11891100 \" target=\"_blank\">",
"        11891100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimura S, &ldquo;Zonisamide-Induced Behavior Disorder in Two Children,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1994, 35(2):403-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/8156965/pubmed\" id=\"8156965\" target=\"_blank\">",
"        8156965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leppik IE, &ldquo;Zonisamide,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1999, 40(Suppl 5):S23-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/ 10530691 /pubmed\" id=\" 10530691 \" target=\"_blank\">",
"        10530691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oommen KJ and Mathews S, &ldquo;Zonisamide: A New Antiepileptic Drug,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1999, 22(4):192-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/10442247/pubmed\" id=\"10442247\" target=\"_blank\">",
"        10442247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suzuki Y, Nagai T, Ono J, et al, &ldquo;Zonisamide Monotherapy in Newly Diagnosed Infantile Spasms,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1997, 38(9):1035-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/9579944/pubmed\" id=\"9579944\" target=\"_blank\">",
"        9579944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suzuki Y, &ldquo;Zonisamide in West Syndrome,&rdquo;",
"      <i>",
"       Brain Dev",
"      </i>",
"      , 2001, 23(7):658-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/11701273/pubmed\" id=\"11701273\" target=\"_blank\">",
"        11701273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yanai S, Hanai T, and Narazaki O, &ldquo;Treatment of Infantile Spasms With Zonisamide,&rdquo;",
"      <i>",
"       Brain Dev",
"      </i>",
"      , 1999, 21(3):157-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/52/25415/abstract-text/10372900/pubmed\" id=\"10372900\" target=\"_blank\">",
"        10372900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12612 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-201.248.109.99-36184B143A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25415=[""].join("\n");
var outline_f24_52_25415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056150\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056143\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236224\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236209\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874937\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056155\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056146\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056154\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790269\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236271\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056158\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056142\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056141\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236259\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236218\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056160\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236232\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056149\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056153\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056140\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056157\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056148\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806712\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12612\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12612|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=related_link\">",
"      Zonisamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/25/35221?source=related_link\">",
"      Zonisamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_52_25416="Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis";
var content_f24_52_25416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/52/25416/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/52/25416/contributors\">",
"     Timothy E Lotze, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/52/25416/contributors\">",
"     Donald J Chadwick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/52/25416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/52/25416/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/52/25416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/52/25416/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/52/25416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute disseminated encephalomyelitis (ADEM), also known as postinfectious encephalomyelitis, is a demyelinating disease of the central nervous system that typically presents as a monophasic disorder associated with multifocal neurologic symptoms and encephalopathy.",
"   </p>",
"   <p>",
"    ADEM must be distinguished from other central inflammatory demyelinating conditions of childhood, including multiple sclerosis and clinically isolated syndromes that include optic neuritis, transverse myelitis, and neuromyelitis optica (Devic's disease). Most of these conditions are thought to be caused by immune system dysregulation triggered by an infectious or other environmental agent in a genetically susceptible host.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, pathogenesis, clinical features, and diagnosis of ADEM in children. Treatment and prognosis of ADEM in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADEM is an uncommon illness; the estimated incidence in California is",
"    <span class=\"nowrap\">",
"     0.4/100,000",
"    </span>",
"    population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/1\">",
"     1",
"    </a>",
"    ], and in Canada is",
"    <span class=\"nowrap\">",
"     0.2/100,000",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately three to six cases are seen each year at regional medical centers in the United States, United Kingdom, and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. There is no specific ethnic distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/1\">",
"     1",
"    </a>",
"    ]. Several studies indicate a slight male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Postinfectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADEM is often preceded by a viral or bacterial infection, usually in the form of a nonspecific upper respiratory infection. In three series, an antecedent infection could be identified in 72 to 77 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3,4,7\">",
"     3,4,7",
"    </a>",
"    ]. A seasonal distribution also has been observed, with most cases presenting in the winter and spring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In general, patients will present within one month of their illness.",
"   </p>",
"   <p>",
"    Numerous pathogens have been associated with the disorder. Viruses that have been implicated include coronavirus, coxsackie, cytomegalovirus, Epstein-Barr, herpes simplex, hepatitis A, HIV, influenza, measles, rubella, varicella zoster, and West Nile virus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6,8-16\">",
"     6,8-16",
"    </a>",
"    ]. Other organisms associated include Borrelia burgdorferi, Chlamydia, Leptospira, Mycoplasma pneumoniae, Rickettsia, and beta hemolytic Streptococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6,17\">",
"     6,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Postvaccinial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than 5 percent of all ADEM cases follow immunization. Postvaccinial ADEM has been associated with immunization for rabies, hepatitis B, influenza, Japanese B encephalitis,",
"    <span class=\"nowrap\">",
"     diphtheria/pertussis/tetanus,",
"    </span>",
"    measles, mumps, rubella, pneumococcus, polio, smallpox, and varicella [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/17\">",
"     17",
"    </a>",
"    ]. No infectious agent is isolated in most cases.",
"   </p>",
"   <p>",
"    Currently, measles, mumps, and rubella vaccination are most often associated with postvaccination ADEM. It is important to recognize the significant difference between the incidence of ADEM associated with the live measles vaccination (1 to 2 per 1 million) and the incidence of ADEM previously associated with the measles virus infection (1 in 1000) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/18\">",
"     18",
"    </a>",
"    ]. Introduction of vaccination has markedly reduced the occurrence of measles in developed countries, although vaccine-associated ADEM is described in 2 cases per 1 million.",
"   </p>",
"   <p>",
"    The Collaborating Center for Reference and Research on Viral Hepatitis of the World Health Organization has suggested a maximal period of three months to diagnose a vaccination-associated ADEM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of ADEM is incompletely understood. However, ADEM appears to be an autoimmune disorder of the central nervous system that is triggered by an environmental stimulus in genetically susceptible individuals. The proposed mechanism is that myelin autoantigens, such as myelin basic protein, proteolipid protein, and myelin oligodendrocyte protein, share antigenic determinants with those of an infecting pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epstein-Barr virus provides an example of this. The virus contains a pentapeptide sequence in its nuclear antigen (EBNA) that shares sequence homology with an epitope of myelin basic protein, a major protein of the myelin sheath [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/20\">",
"     20",
"    </a>",
"    ]. Antiviral antibodies or a cell-mediated response to the pathogen cross react with the myelin autoantigens, resulting in ADEM. Epstein-Barr virus has been implicated in the pathogenesis of multiple sclerosis, in part based upon this concept of molecular mimicry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\", section on 'Environmental triggers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This mechanism is also supported by studies of lymphocytes in children with ADEM. In one report, the frequency of T cell lines that reacted to myelin basic protein was 10 times higher in patients with ADEM compared with those with encephalitis or normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunopathological events leading to ADEM can be divided into two major phases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial T cell priming and activation",
"     </li>",
"     <li>",
"      Subsequent recruitment and effector phase",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Priming and activation phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The priming phase occurs in systemic secondary lymphoid organs, where the antigen-presenting cell presents myelin protein antigen and peptides to neuroantigen-reactive T cells. The activated T cells expand and then migrate to the central nervous system via the postcapillary venules into the perivascular space. In the Virchow-Robin space, the T cells re-encounter their cognate antigen, in the context of human leukocyte antigen (HLA) class II molecules expressed by dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/22\">",
"     22",
"    </a>",
"    ]. This reactivation allows the T cells to migrate through the glial limitans and enter the brain parenchyma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recruitment and effector phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further recruitment occurs through the production of cytokines and chemokines by antigen-presenting cells and activated T cells, promoting migration into the central nervous system of additional T cells as well as other leukocytes such as poly- and monomorphonuclear phagocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breakdown of the blood-brain barrier occurs by release of proteases from recruited mast cells, T cells, and monocytes. In addition, there is production of reactive oxygen radicals, causing further endothelial injury. This leads to the effector phase, in which T cells have more of a secondary role to other inflammatory processes that cause demyelination and axonal injury. These include oxygen and nitrogen radicals, tumor necrosis factor-a, direct and indirect complement activation, antibody-dependent cellular toxicity, myelin phagocytosis, direct axonal injury by CD8+ cytotoxic T lymphocytes, protease secretion, and oligodendrocyte apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/23\">",
"     23",
"    </a>",
"    ]. Glutamate-mediated excitotoxic injury of the oligodendrocytes also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inflammatory process continues for a few days to two weeks, resulting in stretches of demyelinated axons, some of which may be transected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The repair process begins with activation and proliferation of astrocytes. There is clearing of debris by macrophages and increased production of anti-inflammatory cytokines and various growth factors by resident cells and T cells. Oligodendrocyte precursors become activated and, along with surviving oligodendrocytes, begin the process of remyelination.",
"   </p>",
"   <p>",
"    The clinical and imaging outcome of ADEM most often shows complete recovery. However, there may be subtle differences in repaired myelin compared with uninjured myelin, including altered thickness and redistribution of sodium channels. In addition, the relative composition of myelin peptides is altered to forms that may have increased vulnerability to further damage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/25\">",
"     25",
"    </a>",
"    ]. This may explain recurrent forms of ADEM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathology of ADEM in humans is similar to an animal model of experimental allergic encephalomyelitis (EAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/8,26,27\">",
"     8,26,27",
"    </a>",
"    ]. In this model, injections of brain extracts in rabbits cause some animals to manifest an encephalitic-like disease process associated with demyelination. The demyelination appears to result from a cell-mediated delayed hypersensitivity reaction.",
"   </p>",
"   <p>",
"    The histologic appearance of EAE includes perivenous demyelination and inflammation, with an abundance of lymphocytes and macrophages. Lesions often have a flame-like appearance that is similar to pathologic findings in humans with ADEM. They are usually distinct from the lesions of multiple sclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A febrile illness occurs in 50 to 75 percent of children in the four weeks prior to the onset of typical neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/19\">",
"     19",
"    </a>",
"    ]. Neurologic symptoms typically appear 4 to 13 days after the infection or vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3-5,7\">",
"     3-5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever, headache, vomiting, and meningismus are often present at the time of initial presentation and may persist during the hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. Encephalopathy is a characteristic feature and usually develops rapidly in association with multifocal neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6\">",
"     6",
"    </a>",
"    ]. New clinical symptoms may develop during hospitalization. Progression of neurologic signs to maximum deficits usually occurs over four to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. The level of consciousness ranges from lethargy to frank coma. While the alteration in mental state often raises concern for the possibility of seizures, these occur in only one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/7,29\">",
"     7,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to encephalopathy, the most common neurologic features of ADEM include long tract (pyramidal) signs, acute hemiparesis, cerebellar ataxia, cranial neuropathies including optic neuritis, and spinal cord dysfunction (transverse myelitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/4-7,28,29\">",
"     4-7,28,29",
"    </a>",
"    ]. Aphasia, movement disorders, and sensory deficits are less common.",
"   </p>",
"   <p>",
"    Symptoms of optic neuritis include vision loss, pain with eye movement, and an afferent pupillary defect. Inflammation of the optic disc may be seen on direct funduscopic examination if there is extensive involvement of the optic nerve. Patients with retrobulbar optic neuritis typically have a normal funduscopic examination. Direct imaging of the optic nerve with a gadolinium-enhanced MRI of the brain and orbits is a more sensitive means to diagnose optic neuritis in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link\">",
"     \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of transverse myelitis include flaccid paralysis of the legs with a sensory level on examination. The arms can be involved if the demyelinating lesion is in the cervical cord. Respiratory failure may occur with high cervical lesions that extend into the brainstem. Bowel and bladder involvement secondary to spinal cord disease results in constipation and urinary retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severe phase of ADEM typically lasts from two to four weeks. Children may deteriorate after hospital admission, and many develop new neurologic signs. Patients usually recover completely from the acute illness, although some have neurologic sequelae. In the three contemporary series noted above, all affected patients survived [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute hemorrhagic leukoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory hemorrhagic demyelination of central nervous system white matter is seen in rare conditions that are considered to be hyperacute variants of ADEM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6,30-32\">",
"     6,30-32",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute hemorrhagic leukoencephalitis (AHL)",
"     </li>",
"     <li>",
"      Acute hemorrhagic encephalomyelitis (AHEM)",
"     </li>",
"     <li>",
"      Acute necrotizing hemorrhagic leukoencephalitis (ANHLE) of Weston Hurst",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These hemorrhagic variants are more rapidly progressive and more severe than typical ADEM. Otherwise, their symptomatology is similar to ADEM, with meningismus, headache, seizures, multifocal neurologic signs, asymmetrical neurologic deficits, and coma. They typically follow an upper respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain imaging with MRI may reveal diffuse white matter lesions, often large and associated with cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. White matter lesions can be detected on MRI within 72 hours of the first symptoms, but hemorrhage itself is not necessarily seen with conventional T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences. Specialized spin-echo MRI sequences are more readily able to identify the acute hemorrhage associated with this form of ADEM.",
"   </p>",
"   <p>",
"    The cerebrospinal fluid typically shows both white and red blood cells, with increased protein concentration.",
"   </p>",
"   <p>",
"    Some patients recover with treatment. However, the prognosis for survival and recovery of neurologic function is worse for AHL than ADEM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MRI abnormalities are best defined by T2-weighted images and fluid-attenuated inversion recovery (FLAIR) sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68014 \" href=\"UTD.htm?34/12/35010\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/36\">",
"     36",
"    </a>",
"    ]. Contrast enhancement is seen at times in acute lesions. Findings may progress over a relatively short period of time, consistent with evolution of the disease process.",
"   </p>",
"   <p>",
"    Computer tomography (CT) scans are often normal, and thus, are not helpful.",
"   </p>",
"   <p>",
"    Abnormalities on MRI vary in location. Lesions associated with ADEM are typically bilateral but may be asymmetric and tend to be poorly marginated. Almost all patients have multiple lesions in the deep and subcortical white matter, characteristic of demyelination. The periventricular white matter is often spared.",
"   </p>",
"   <p>",
"    Multiple brain lesions are typically present, but the number varies among patients. As an example, patients in one study had from 4 to 56 brain lesions on the initial MRI scan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/5\">",
"     5",
"    </a>",
"    ]. While the lesions in ADEM are often large, smaller lesions are also seen, with diameters ranging from &lt;5 mm to 5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3,5,7\">",
"     3,5,7",
"    </a>",
"    ]. The large lesions may have associated mass effect.",
"   </p>",
"   <p>",
"    Gray matter lesions sometimes accompany the white matter abnormalities in ADEM, especially in children. The thalami and basal ganglia are frequently affected (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68014 \" href=\"UTD.htm?34/12/35010\">",
"     image 1",
"    </a>",
"    ), and lesions in these locations are often symmetrical [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/7,37\">",
"     7,37",
"    </a>",
"    ]. In contrast, supratentorial lesions are usually asymmetrical.",
"   </p>",
"   <p>",
"    Brainstem and spinal cord abnormalities on MRI are common in ADEM (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68014 \" href=\"UTD.htm?34/12/35010\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76694 \" href=\"UTD.htm?8/46/8935\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. In the spinal cord, large confluent intramedullary lesions that extend over multiple segments are typical [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/5\">",
"     5",
"    </a>",
"    ]. Enhancement is variable.",
"   </p>",
"   <p>",
"    Hemorrhagic demyelinating lesions are seen in the hyperacute ADEM variants that include acute hemorrhage leukoencephalitis, acute hemorrhagic encephalomyelitis, and acute necrotizing hemorrhagic leukoencephalitis of Weston Hurst. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Acute hemorrhagic leukoencephalitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Imaging often improves with convalescence, although lesions sometimes persist (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76694 \" href=\"UTD.htm?8/46/8935\">",
"     image 2",
"    </a>",
"    ). Among 19 patients studied two months to nine years after demyelination, lesions resolved completely in seven, partially in 10, and remained unchanged in two [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3\">",
"     3",
"    </a>",
"    ]. None developed new lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of inflammation is common in cerebrospinal fluid (CSF), with pleocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased protein concentration in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, the CSF can also be normal.",
"   </p>",
"   <p>",
"    Some patients with ADEM have oligoclonal bands in CSF, due to intrathecal synthesis of limited classes of immunoglobulins that are depicted as discrete bands on agarose gel. Oligoclonal bands are a nonspecific finding more often associated with multiple sclerosis; they may also occur in chronic central nervous system infections, viral syndromes, and neuropathies.",
"   </p>",
"   <p>",
"    Investigation for infectious agents usually includes viral cultures of the throat and nasopharynx, stool, and CSF and serologic testing for a variety of agents, including influenza, Epstein-Barr virus, herpes, varicella, mycoplasma, cytomegalovirus, and rubella. These studies are rarely positive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children have nonspecific findings of inflammation. Leukocytosis is common, occurring in up to two-thirds of patients in the three series noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. This is predominantly due to lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/17\">",
"     17",
"    </a>",
"    ]. The erythrocyte sedimentation rate and C-reactive protein concentration may be increased.",
"   </p>",
"   <p>",
"    The electroencephalogram (EEG) is not diagnostic. It may show background slow wave activity that is typical of an encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/17\">",
"     17",
"    </a>",
"    ]. Seizure activity is rarely seen. In patients with optic neuritis, visual-evoked potentials may be prolonged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ADEM is based upon the clinical and radiologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6,36\">",
"     6,36",
"    </a>",
"    ]. There is no specific biologic marker or confirmatory test.",
"   </p>",
"   <p>",
"    The diagnosis should be suspected in a child who develops multifocal neurologic abnormalities with encephalopathy (eg, confusion, excessive irritability, or altered level of consciousness), particularly if onset occurs one to two weeks after a viral infection or vaccination.",
"   </p>",
"   <p>",
"    Bacterial and viral meningitis or encephalitis must be considered and ruled out. Empiric treatment with broad-spectrum antibiotics and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    should be considered until an infectious etiology is excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H3#H3\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=see_link&amp;anchor=H8#H8\">",
"     \"Viral meningitis: Management, prognosis, and prevention in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory studies should include a complete blood count and lumbar puncture. Cultures and serologic studies should be performed on blood and cerebrospinal fluid to detect bacterial and viral organisms. Viral cultures should be obtained from nasopharynx and stool.",
"   </p>",
"   <p>",
"    MRI of the brain and spine is important in establishing the diagnosis of ADEM. The abnormalities are best defined by T2-weighted images, FLAIR sequences, and contrast-enhanced MRI with gadolinium. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sequential imaging by MRI during follow-up is sometimes required to confirm the diagnosis of ADEM, as the development of relapses with new lesions on MRI is not compatible with a diagnosis of monophasic ADEM, and suggests that the correct diagnosis is either multiphasic ADEM or multiple sclerosis (MS), depending on the clinical and imaging features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Recurrent and multiphasic ADEM'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"     \"Differential diagnosis of acute central nervous system demyelination in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for ADEM in children have been proposed by the International Pediatric Multiple Sclerosis Study Group (",
"    <a class=\"graphic graphic_table graphicRef74896 \" href=\"UTD.htm?24/17/24860\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/38\">",
"     38",
"    </a>",
"    ]. The major criteria are a first clinical attack of central nervous system demyelinating disease with acute or subacute onset, polysymptomatic neurologic features, and encephalopathy. Brain MRI criteria require focal or multifocal lesions predominantly involving the white matter, without evidence of previous white matter changes.",
"   </p>",
"   <p>",
"    Encephalopathy as a presenting symptom is required for the diagnosis according to the Study Group criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/38\">",
"     38",
"    </a>",
"    ]. Encephalopathy is defined to include either behavioral changes, such as lethargy or irritability, or more severe alterations in the level of consciousness such as coma. The onset of the encephalopathy must correspond with the occurrence of the disease state. This feature helps to distinguish ADEM from other clinically isolated syndromes, which have a greater risk for recurrence and subsequent diagnosis of MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"     \"Differential diagnosis of acute central nervous system demyelination in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic criteria also distinguish between monophasic ADEM with early relapses and recurrent forms of ADEM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Monophasic ADEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single clinical episode of ADEM may evolve over as long as three months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/52/25416/abstract/38\">",
"     38",
"    </a>",
"    ]. Any new and fluctuating symptoms occurring within three months of the initial event are considered to be part of the same inciting event. In addition, symptoms that appear during glucocorticoid taper or within one month of completing a glucocorticoid taper are considered to be part of the same inciting event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Recurrent and multiphasic ADEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent ADEM and multiphasic ADEM are the two relapsing forms of the disease. Both forms are defined to occur more than three months after the initial event and more than one month after completion of glucocorticoids. By definition for ADEM, both must include a clinical presentation with encephalopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent ADEM describes the recurrence, three or more months after the first ADEM event, of the same symptoms that occurred at the time of the initial presentation. The MRI findings are also similar to the initial event and are without new lesions, although there may be enlargement of the original lesions.",
"     </li>",
"     <li>",
"      Multiphasic ADEM describes recurrent disease that meets criteria for ADEM but involves new anatomic areas of the central nervous system. Symptoms and neuroimaging findings are different from the initial event, with the exception that symptoms and signs of encephalopathy may not differ from the initial episode. The MRI must show new lesions compared with the first attack and demonstrate complete or partial resolution of the lesions associated with the first ADEM episode.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a child who presents with neurologic abnormalities, including signs of encephalitis, bacterial and viral meningitis or encephalitis must be considered and ruled out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H3#H3\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of nonspecific cerebrospinal fluid abnormalities, and MRI evidence of white matter lesions, other inflammatory demyelinating disorders should be considered. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple sclerosis",
"     </li>",
"     <li>",
"      Optic neuritis",
"     </li>",
"     <li>",
"      Transverse myelitis",
"     </li>",
"     <li>",
"      Neuromyelitis optica (Devic disease)",
"     </li>",
"     <li>",
"      Other rare conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of central nervous system demyelinating disorders in children is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"     \"Differential diagnosis of acute central nervous system demyelination in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute disseminated encephalomyelitis (ADEM), also known as postinfectious encephalomyelitis, is a demyelinating disease of the central nervous system that typically presents as a monophasic disorder associated with multifocal neurologic symptoms and encephalopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ADEM is an uncommon illness that is preceded by a viral or bacterial infection in approximately 75 percent of cases. Less than 5 percent of ADEM cases follow immunization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ADEM is considered an autoimmune disorder that is triggered by an environmental stimulus in genetically susceptible individuals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with ADEM present with fever, meningeal signs, and acute encephalopathy and have evidence of inflammation in blood and cerebrospinal fluid. Progression of neurologic signs to maximum deficits usually occurs over four to seven days. The level of consciousness ranges from lethargy to frank coma. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflammatory hemorrhagic demyelination of central nervous system white matter is seen in rare conditions that are considered to be hyperacute variants of ADEM. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute hemorrhagic leukoencephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep and subcortical white matter lesions are associated with ADEM on brain MRI, and are typically multiple and bilateral but may be asymmetric (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68014 \" href=\"UTD.htm?34/12/35010\">",
"       image 1",
"      </a>",
"      ). Brainstem and spinal cord abnormalities are common. Gray matter lesions may be observed in the thalami and basal ganglia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ADEM is based upon the clinical and radiologic features. Diagnostic criteria for ADEM in children have been proposed (",
"      <a class=\"graphic graphic_table graphicRef74896 \" href=\"UTD.htm?24/17/24860\">",
"       table 1",
"      </a>",
"      ). In a child who presents with signs of encephalitis, bacterial and viral meningitis or encephalitis must be considered and ruled out. A lumbar puncture and MRI of the brain and spinal cord should be performed whenever the diagnosis of ADEM is suspected. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ADEM includes other inflammatory demyelinating disorders. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"       \"Differential diagnosis of acute central nervous system demyelination in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/1\">",
"      Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/2\">",
"      Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009; 72:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/3\">",
"      Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 Pt 12:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/4\">",
"      Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/5\">",
"      Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/6\">",
"      Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007; 68:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/7\">",
"      Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/8\">",
"      Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol 1998; 91:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/9\">",
"      St&uuml;ve O, Zamvil SS. Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol 1999; 12:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/10\">",
"      Caldemeyer KS, Smith RR, Harris TM, Edwards MK. MRI in acute disseminated encephalomyelitis. Neuroradiology 1994; 36:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/11\">",
"      David P, Baleriaux D, Bank WO, et al. MRI of acute disseminated encephalomyelitis after coxsackie B infection. J Neuroradiol 1993; 20:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/12\">",
"      Kim SC, Jang HJ, Han DJ. Acute disseminated encephalomyelitis after renal transplantation in patients with positive Epstein-Barr virus antibody. Transplant Proc 1998; 30:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/13\">",
"      Shoji H, Kusuhara T, Honda Y, et al. Relapsing acute disseminated encephalomyelitis associated with chronic Epstein-Barr virus infection: MRI findings. Neuroradiology 1992; 34:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/14\">",
"      Apak RA, K&ouml;se G, Anlar B, et al. Acute disseminated encephalomyelitis in childhood: report of 10 cases. J Child Neurol 1999; 14:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/15\">",
"      Huber S, Kappos L, Fuhr P, et al. Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni. J Neurol 1999; 246:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/16\">",
"      Murthy JM. MRI in acute disseminated encephalomyelitis following Semple antirabies vaccine. Neuroradiology 1998; 40:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/17\">",
"      Stonehouse M, Gupte G, Wassmer E, Whitehouse WP. Acute disseminated encephalomyelitis: recognition in the hands of general paediatricians. Arch Dis Child 2003; 88:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/18\">",
"      Fenichel GM. Neurological complications of immunization. Ann Neurol 1982; 12:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/19\">",
"      Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005; 62:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/20\">",
"      Bray PF, Luka J, Bray PF, et al. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992; 42:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/21\">",
"      Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med (Berl) 2006; 84:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/22\">",
"      Greter M, Heppner FL, Lemos MP, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005; 11:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/23\">",
"      Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/24\">",
"      Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/25\">",
"      Whitaker JN, Kirk KA, Herman PK, et al. An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8. J Neuroimmunol 1992; 36:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/26\">",
"      Bauer J, Stadelmann C, Bancher C, et al. Apoptosis of T lymphocytes in acute disseminated encephalomyelitis. Acta Neuropathol 1999; 97:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/27\">",
"      Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000; 6:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/28\">",
"      Brass SD, Caramanos Z, Santos C, et al. Multiple sclerosis vs acute disseminated encephalomyelitis in childhood. Pediatr Neurol 2003; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/29\">",
"      Davis LE, Booss J. Acute disseminated encephalomyelitis in children: a changing picture. Pediatr Infect Dis J 2003; 22:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/30\">",
"      Seales D, Greer M. Acute hemorrhagic leukoencephalitis. A successful recovery. Arch Neurol 1991; 48:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/31\">",
"      Klein CJ, Wijdicks EF, Earnest F 4th. Full recovery after acute hemorrhagic leukoencephalitis (Hurst's disease). J Neurol 2000; 247:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/32\">",
"      Rosman NP, Gottlieb SM, Bernstein CA. Acute hemorrhagic leukoencephalitis: recovery and reversal of magnetic resonance imaging findings in a child. J Child Neurol 1997; 12:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/33\">",
"      Lieberman AP, Grossman RI, Lavi E. Case of the month: April 1997--a 32 year old man with mental status changes and a severe occipital headache. Brain Pathol 1998; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/34\">",
"      Kuperan S, Ostrow P, Landi MK, Bakshi R. Acute hemorrhagic leukoencephalitis vs ADEM: FLAIR MRI and neuropathology findings. Neurology 2003; 60:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/35\">",
"      Mader I, Wolff M, Niemann G, K&uuml;ker W. Acute haemorrhagic encephalomyelitis (AHEM): MRI findings. Neuropediatrics 2004; 35:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/36\">",
"      Alper G. Acute disseminated encephalomyelitis. J Child Neurol 2012; 27:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/37\">",
"      Baum PA, Barkovich AJ, Koch TK, Berg BO. Deep gray matter involvement in children with acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 1994; 15:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/52/25416/abstract/38\">",
"      Krupp LB, Banwell B, Tenembaum S, International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68:S7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6184 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-6600BC86A8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25416=[""].join("\n");
var outline_f24_52_25416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Postinfectious",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Postvaccinial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Priming and activation phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recruitment and effector phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute hemorrhagic leukoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Monophasic ADEM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Recurrent and multiphasic ADEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6184|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/12/35010\" title=\"diagnostic image 1\">",
"      Brain and spine MRI of child with ADEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/46/8935\" title=\"diagnostic image 2\">",
"      MRI of boy with ADEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6184|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/17/24860\" title=\"table 1\">",
"      Diagnostic criteria ADEM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=related_link\">",
"      Differential diagnosis of acute central nervous system demyelination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=related_link\">",
"      Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=related_link\">",
"      Viral meningitis: Management, prognosis, and prevention in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_52_25417="Inhaler instructions";
var content_f24_52_25417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    How to use your metered-dose inhaler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 657px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25417=[""].join("\n");
var outline_f24_52_25417=null;
var title_f24_52_25418="Lichenoid drug eruption";
var content_f24_52_25418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80165%7EDERM%2F59258%7EDERM%2F71210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80165%7EDERM%2F59258%7EDERM%2F71210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous to violaceous papules with fine scale are present in this patient with a lichenoid drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lichenoid drug eruption manifesting as violaceous and hyperpigmented papules is present in this patient with dark skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides chronica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtfLHmDLZBqQKADz04FTR26gMzN9KY67Y2IIPYV5tj2ea5A2RIppwb7xIwKHDnbtIyKVCzKd6jHrQDHxhVQ579KVGJYhjjtSBt7Kp6ChoyzBicDrxQSGwbmOaZmQcMMr69xSkjDZ6HvTTKwIVc47E0DsNMnzbB92j7su5FDKBTgo3tuGaJMLFwCuaQvIjBADMT16gikR8oVPT1o3BUX5vm96gnmY4QKFHXIqthpD2J3AEkAdzSvIEiVQATnmo12nhwcetNjY4YiP6Z7UXHYlcHAY7eTjpQz5dUOFx3xUOWKghhu9KXk8FhkdaLjsDIA33cjqMU0jfIRgDHPNJLIYfugtjtmokZXcs3AJ6VDZSRcidQhCEgdcGlUgZxzkdPWq8MgzgcDPWrQIVQcdDkcUPUTJFAYgg4PfNPDEOCpAHc1DHIz5JGMc08EkgYwPzoQrE52sQx6elIjZwU+7nGDTJCc7eCcdabyUw3FMSVivND85fbx9KdbBVOF5OeD6U8kqwQHKjqCetKPRTjPepsac11YkBZFYFSc9zQrfL90qoHJzwaV1JjILDP1qL5toy/yD07UyRTguWB/D1p5wUGQM0hKMMrkkd6SRyAPLAK9TxzUobFLbnBJPTB7ZphDorIKkVVOGZsDGcUinBcgjiqEOiiOdw2nGBn0qVthPPDfSoos7VZc7h27VJMplVXBAbqaBPcTftUlmwf51EC6ncVwp74qVR0wANvUnrTXc7vnY7OoFFxiZBYMWUEjHFOc7mLFuMDJxSSopKYOCw4OO9IF3wsAeF6n0pgCMIwCvzd8ZoM64wQqD1qNlJXdH97vmopIw5APG3tSu07jsmQkYlYIykA7Qy9DU6bc4yVx3pFRVbywBjH3j60Iqr/AKzOB6UN31Bse5BcnI+tRksqYYFfcnNOxlSSvy55NRk7iRJ0A4pAhZAGAJcBcdu5psTB9xU5B7HsKY53KCCAGGMYpwVdgcjjOAB1NCGPXOB14OdvWo5nXcCFwewNNMpjcgcLnBqJhlyRyc9c9qdwsNbeHLJ97sKYwbBIH196XA2Hk7/r1pE3bQG6Hg1IyNgBtHzAnuDTJGBZSQSw4wKfNGA4CnAHcnvUbEDncxA7jrmqEKXRly/yYGcZ71E/JKnj0zUU+NqnJDAkc0mSOAGDepOc0XKaO1C9i3FQlQysN3Q9KthkMQIBJHFRYUbTkFueKuxzIaFDKNuQDSuoRNvU0Hae5GfelwmcMc4H40BcjkPzZIAwOMGo1Z2jw20Z7g1I4DfdzhaiVTJ2IWizGrDSjMoUnkd6j+bcQu447jtVhjtAUjA9ahy+XWPhT39afKUmPjO49SWxzTZchwoXrRb7/n4G5abkn5iSSe1FkJrUbJtO4uOewqLYM8Ee+amcBSc/lURO0AYOc9aBjXBBUKM01m3uoZePQVM4YSFhhjUW3bJlSCT6VLGmNQASMACeOBnpTI22yMXAIp6jDF1+8e9MkU+WG754FA1uMkcEnJOf4RSsuWBfgY5ApxYsQ2B7Uzc5lG7mlZFXJlIXoPpinJI0gYuSO2O1NY7m2oFIHPPengktlhwKRJLHn7p9O3SpNoRsOcE+lRRnJOD7806ZgFy2T7ChAydQGC7n27R370jSqxOckjniqquZCHCnb057VKobJOMU7hyj2KnLcBvX3ppbkArk9AcYpI0HVjnNKxO8qDlR0+tILEixqFG5huPr2pj7NnUFgcHFMJBbBbr2pCgEh3Y20gSsORtg+98rcjHaguAT5ZIB4Jx1pXcLwi5HrSKfKBLYbt0o0GSRxq4IySwGfrTUCiPqACcY70oYbeDkilkVSQGXn1phqKsZJG1vl7DpTycKMHn0qJEAIw3fqKftIO3369hQAkxByWJB64B70xXKBgQQxHenMu6TG5WPr2pVxvYSYJ9aLACyKyEM2ABxSFdy4Cjryc0jKGTa3GOnvTgmEzvGeAaAJVClFWMHcR82ai+bJDYGOmRUodlOAFBxULkyN+8yOvOaSZC3EkC8ktuI6+gFJI4X5iQFxwPWmqWUZXlc4OfSmupDFJR1PB74ovYsjc5O1A3lnn6mgbmBAwOO9LtZmGz8/QUuxcrkYyMk0agMPyLhtuQvX0pJFLbXQZOOWJ60MOJAW+X270yeUoQFYDI7HOKdwGyKGAJGMt1qKRh8oGAO+aJHeN02tnPJJHAqNl8s/McjqKncoeDgleCpPWosYflsDtzSNghjhvam4VXDyAsMcAdqWowcvnbHgnOTnpUJdzhscdCegq26RyYC/e7qD7darOyr8pYtnp6CrsTe5C7L84HzZ6UuGCjtxnNNkV0QDAy3Q0jOycSSdegoGzt/MRGKxnKng0bgicrge/WmoVDKSCMe1ExyRkbh1rZKxzgjb0JPC5/GnKmccHk02BULjcCATV3y/MfCOPl5ANOML6kydilMQu4HgCq7ZMIK9M8jNWrnHnYcg46VTZlJPzYPtSejKiO3KVGRmlRz0VQAKjV/LPTr1p7HjcBgd8UJ2GKIgscjbsg+1V0kbAwOnTNTSyMyjnjHHtUUSb2VU6nrmlKSewxoZ5SWYcDmozli2RgZzmp5P7nAA9KqszLGVOSDUghzj92xRjjr71DvKBfm5NJuBJPIGKjVsKcoduOtTctIseYSQSowOw70zzuDwfTFNLBTvViFApuT5fynI9fWmFgZl2rtfI9u1EYLSFxke9MVQ67h970FPKtkFeB35pDJgoB6gnPSpMEsWHAPBqNTu4HUetS7hgFeWzSYrij5QMD5qVRkYc855FNXcWAOSoNStgsMEAd6EAqbQ2CMKeMZ6U99igMWPzdMc02NUDgYyT+lO+b5digHJG09c+tO1xojL5GQQtNYjsR9RU4Riu1gA2MknrVaVcEFQSRRJWAaSNu7ndn8KkR8qNwIWmOfMTPAYH7tKNyqMtk9MntWd7DHKQQyhiB3z3ohfK+v1HSmAFlwRuPqKcD+7xnBBptgTjlQgXk8/jSfMMB/lA7UinaM5yxHFMaCRUJclSy5B/vU0m1dCJHIDcbj6YqRs4y2cZyBmq8LlY8Dhj2IzinZLth8biMmi4NDyAxO3j1FJlMtwScc5poVshwfl9D2p6vlm44I6UwCNkIBY5K8/SnKUIbqc9vaoAVKlMHJ5JFPOCq7OW6fSkFhzMwUFmCgcYNBj2gDeOPmBqNsMck/NnHWpCY1QbjnI6dRQJ6CSOu7CN8rVG42vkneeuDSuQg5XCYz8oqMbVk4cBCMk0mApLDcCMKe9NZ8A5ORjFMlBd/3bBlTBz1okJPKnr2xTuMjOdzMw+VuBmnlQpJJGcdhUIfuRkg9qkBCuRnK9QTxQNkLSEISyFsdMDoKikZR5ez5uOCRwakfOSGz7emaikK+SqhssD0HaktwQycF2bccHgcHimpIFBAQZycE8VLuLbRtAPr2NRTgJkZ3j1U8D8aplJ3EuHB4YkDg4z1PpUEjbTuUZz0B6fWkbe0oLD5R2psbD5gQcHge1F7g1YVhtIbeCQMk/wBKZkGQugJHqf6U7dtAwAzA8k/4VDLt5bgY4P1oJudy5YEInJ9KkRWKYYDdTNwVt44Y9CariR3f52FbGFrot7mTaSc81cSZSwfywPeqBJYKM8AflSeY+xgpwB3qlJxJcbjbyUOzALz3qHC7Mtzzke1SZVVx829qY6sc5xtA59qi99TRaCEEA5OR2qQRlFzk8jpUWU34zjjrUbFl5DHA6CgGrkhw23gZz2oPDkscGmI6/eLYb2oZlJy2Seo4pWJGSgYZg2D2qEh/vZycd6kL4ORgnoRjpUDEu/Xj1/pUsqISMRgccck0mS/8OFHXNK+AuATwaY7MSQwJ3elCKGs8ZU/KR7Cow/JXOM9hTi3K8YUUipu3lSF7/N1oKQok2Ku3sc5FKWGM9c84qI5KgY56nFPjZsBAAGz19KAY5Hd/lxgjn8Kn8wsq8dOBiq7hvOBJ5xzzU1r+7QliMdSKQWJ43yoP3T3NPbGflOee9RA7gO4PSnS4XhRk9iKNxWHo53/P8x7n0pYpyrbDCCWbiYnkD0qFVOAzEkqenSgKDgY3YORu7VUG4lKxfMscakbsg5/GqUpG7CNnPeoL2TcuYwVI/Oq0ayeW3OFPPPepqO7KjDS9y98hYDPUYyaeMFmwdx7ZqmN+VVznuMd6njKqMouG9KzE1YkgLqrhiAp7Y6UkoUAFVO49O2aVZApyx+bv6CnKmF3MDub7o9aYhrArERtO4jKtnG2i1LbWaR2c4wMnOKcUfaVwcjrk0kfR0Cbdxz7U0+gdByqwlAc47j6U4/OTuYj3NKqnaRI21gOM9eKYPNLbtwO0cjHajTqA6ILtIBOfQ08/IG8wnPYCosSMAdo29M9KeoYMEIUtjIy3SkgBWMrjjy8dSO9IEdx8ilcH160RuHYkLznn0pJQ27DMMfewppiFG0NsIwc8mgjCMeg6Gn5GMIhKd2qNZRnAQZ3Zz6CgEMR2AKqCSafblfmDA56D61FNM3zfeyTwQMVGrZTjejdDzwKE7MbWhLJMocI4AI6larMGLcH5QeTmkmyRkMScjmlVR0JGSdxPvQ3dgloO4OQqfKfzNIzZUDYCR6+lNZiRncSTx7YphYKu5SAvT8KLAKzHzPkzk9h3qq8+x/lG3ceQakXdsDceoqB14cBgCeScZApjVh4ZS2GYEHnNQs2S4DAAdQRS5XaMtuzxxxz71CZMMV4VRx65pD9BzSHZkttQ8EetRF/LKMvPHegnA/eAEDkE1ExUZJHGOT70xj2kKvnAYnqPSoJZOOck9h04pokHlqckH060x3ywPdhyTQKx3khZjuJIx0zTXmHyhlxjkmlKFiW56U4gEhXIOB1q02zHQRC+C4JANOVi7Fd2B1PpTfM+UqvOOOaZkjJxg9OKoQ9sZBLcdsUNvaQlBjd29aazfulJHzd8U7OHQgncevtStqJiFAg6Ec9ahYqXZeTirUiscANzWY7S/af3YGO9OWg46k6xb0JcjAp4c8CMAe9QByyONwGOCMU5W3EbzhR6d6FoJojBf5jznvTARvJ+binSDB+9xUTBjJnbwR0qS4gCWDKSAeuKRnZSNvJxUbKxDcfd4IFNLlWCgBRSKSFDfKS3J7CoidhXByT1z/Kk3ZuMocqeMmlkU5wRuIOc5pD2JQc8KCT39qkHIPAIPf0qEbl+ViCevFOztAUEfMc/SgCVByC3zLUjIeAeCTnA9KS3jIJ5HTr6VJM5QearElflzjOapRdriHMhZMoz5UZJHA+lSEeWiqYyrN824nOQPamxyAxhMNsUbizeppXZpFLljsAwGPb2FXbTQQhIKAgFnz3oUsCd59z7VACSMgHg8U1nC7hlmzz61k5F2FmJUkKwKt3IqrKpZlSV1SP+8Tg1O2woTtPPQjmonUbDvAI7A81Kety49h0YUEBCWUDHWrSbSvJ78YrJDuZsr8i9M561p2sp2nYoPYZFS2mwmrE27y+hDjoeOlHmOrAA5PYelNVWLnbgg/eB6Zp0QZmZdoUkdT04pmY6HcWIeTBxz700NuyrsQp6HoaEfduAOQD0/wDr00/NhZMjHRgKAJ4j5hzGxfAxjHSmZdi2MZ744NJCoBIjLFFOWYcc1M4USgbW59KLXB2Qxo8/NIxPfCnoajJBXklRUs5+6pULnkEnHHpUP+sVi5+YdMdxUsaHohVW8tjsIyT60OwZ0EQJwOp7GiJhtIwxAHPvUcbLv/1ZwemKYupKsrsxyTyfmHtSyYEZIJznp3xTXXkHgDpnNMLbn2oAAvBFMQ3zCkYBkyc0pzuK4BJ9+tI7FlKAKwJ4bFJA583y24cHjJpgNmifzSSuBxgA1GzjcVAIHXpzU8s7mTLKpVeoqpLI6/dwcHj1xTcew1cVpXjBBXAHB55xUUhV4DyQxPOP6U8sCwZWLE1HtAGRnOc49qAGMcELv46Yz0/GmNIu0oGGCOMHFO28NwCzdSO9RsqfKpBBHViOlIdxHVdgywGOgx1qv5pAUZB54AHOfrUjeWowXYgA8Y4qF2+Qh3Hy9No5oGhDIzSZcbPT0H0qFi4yM4HWllflvmLKgzx71AXG0EknjjigYpLtJsJAz2I6UwvEMFlLHp6CkOQ5Y5cd81FOwk2jChBz9aEDPSGbCbSDuPNNyAVG0ipBJG0xKqdtOzsLFhnPQHtWqVjmvYgJG5yzYOO1IZCqKME5PU9afujK52Et3psvViEPTgVSVwuPmz5aYXjvjqadEcyApggDnNZ8Mk6DJY4zjB7VNzHksSM85FHULE85+TdkZJqAqC+xiqYGGbNDhR8inLEZ57UwqpUIRnHUjvTvqCVkI3lx7gj8t+tRMH37OMrzn1oyu1lKnOfve1IdiMGUEAjHPek2MYGXdtOAepOeoqNXD52E5X9adLmY9AATgGj5IRmEjcDg+9QWCr5h27+vJ9qjbaGBIDgcY60owgDsOD2pj4VM4O4nrSYIjaMK2QNq+tMi+Zm2/MpOMHvU77SAEyx7+lQgrsL/ACqM4wPWkMHUKScHn36UqAmUMwwAMcUjPym4dO570pY4GG+U9/Wlewy3FKmSckr2HelebIAJV8cbegFVlGwsVOMdKVcqCCwIHI46mnzMLF3zfk8squcY3Ec49KY0xfjd07HoMUwEAEbjuPNKqlXBbBB7ZqnNtWYiZBvQHI+tRSjoBgY7+tOLEqSFA5/Sm5XOOD3A9KiwxdxAI3fTA6Ubdu1uGPf/AOvTi3loMFScYPekQ/LnPOeahoYSosqqj7RjnAHWnIGVsIOBxj1p0gjMeXbDdhiokZh8xUMSO3aiwEzqd2WBZiOAvb600MpXa7uT6DpSB13ZYmMAcgUEsqlwqsGGAfSmncQo2Bi3OemAegqSJyvLKSqjr0quNqqHjLMe4PSp95KAM24sc4z0oGxxdd27Lbm4x2pJXdZtjgqpHD9vpTFYl/LUhuxB4qzBlpV8/IQfxYzihaiegxZBuwcsoPHvUbMd+cERZxjFWZZEDbly0ZyAu3Gf8aplwCDKWxjlT2+lNqwk7jwcOdmSvbtTfug/wj0aohJsJYBs44yOlRRN5jSZ4JPc9KkqxZZSGDFRs6jnNInqWyxPT0onQxRoyYORyM5A96gQb2LH7v8AETxk1T0YkhzH91kOdwJwv9aiBYFnQhgOue1KeWIC9eQSelQlXQnDYznd70PTUdhzyFnJ+XPoaTe/lYVvvc7cUyVldQVYb+hyOlBfBBHYY4HU07hYVG+ZQcL2wOgo83amCASBgYOT9abjdhWTqeaZKwUuoxjpx/DQLcHZlCBiQc7sDr+NQSSHB3qxT37045Y/IScjBPb8KicDdiQZI468CgY9SozkcEcVWyI3LbQy+p/rTtxGSGBwO/f6VXZypAZgwPO0dKB2Gu3zt84UEc45Bqu7EoOMkcdalZikm5cFRyVxwtVsHKnAUknLE0kO44swDccnr2qCWQIwIVsYxknim7w24bieu7vUDNlD87YHO3rmmJnqwDrEoUg9qkBAlGeSBUMeSvPGe+aliBUsQO2CT3rWxzMjMgdGKnCZ7j+VSFmYKwJGOPwoIWVCCM46U3zFiTDBix6YoV0SQzj53wMn2phyEUHHXoacHHmhxkU3cfLLBR1pmiEf5nLOPl9O9I+1E27cMxzn0FIysWUsTg88UpkQGQHlyMDNCExknAJiIKY5z61AGI+ZjjI4FTOpdVUbCo+YgVCEZmLkDYvQE0mUhjB9igsCp52+lIcqTkAK3ByOlLG37tgCNx9KYd+zczYUcYNSx7iytsZTt49KYGPnfP0xn8KSZlxjJ6jGRTMg55JGMUihXYhuDtU+/UVAhVS4GX9M96lCbXQAggdqjdw7YVwCetIYAZKuxJGMEelOi2pncc1FGW8zB6KefpSu+HZkG4ZyKVx2J0IVsnJwO9OCsBkZyf51CjM8g6/1q07k7Qp2sB+ZpXAeoXZ1BAznmpIxu5I2joKgUrvHyjd1ODVhwAO5I7f0qhCCJ0Y4AJI/zzSsRuUdO2KQscNnrjhfUVGueCcE+o9aV0NIUljwGwAeMilYMrlz0P3sdKVUyMkEvjGPSmnuQuB3BPBqGtRilyjAj5lHPI60mQ2SPlBPQnpTA5VSOw69805VlMYdIw6jGSOooSb2BokdcMvKsBxgCnRgs+2VikZ9elQoGZd2z5f1pxfIG7hwOBmmIVAN5GNqHjcBxUwDRoquuA3IkNQnDIU3SBgeFx1p4cooDZKkYAPShAxjSfu2LAlz0apzMVRBkYI5qFWYxKJU3Bh+VNRNkBUBCx+YZ7U1cLF570xKYk/eOo+UheV/GqOGAJmkLSMfvHnH4+1ODFsYdQ2McDFIXEmyIbBjocU2+bdiWmwwOQ8i7s7sKc+goUJygX5yeMULyMEHIz83v9KVhhAApMg7kdfapSHcSQksFDEIGOVPf3oLK/yKmMdx0oYDzMMDnHRaj+dQxUgI/b2qmG4OQJc7t4PXHSoGLM24nkZAQ1OXygZMAD+ED9ahySB5rHDDOR1oGmOkIVVIAU4646mmkgzBSx5GAwHemDAc7WZgDwvrx6VEpIVAWCsMkEDpQhE7yM28ufmLYJP9KYVLSjd/q8cZ/iqJiAX+bjIH196axAO0tgDBz1FMB0j4yp3Iuc4XpTUQkFl45zsIwahkkHd2GOB/SmCVwhbaeSCSTmgLDzPyFGMMcA9vfFVZ1ZshAAD82SMU+ZkcZGVHUbjnHr+NQSzFg6rnbyoJ9PamwSK7GTMql8g478VE7YbeUOD0BpcbUCkcr1GailYKNwGVAx83r7CpiDYxgImIUIrMdzEDqfeomxk8gx5GD600uATgnpkZ61GzumQoKkDc3/6qAPW4gcBmOM05ZfLyzqx9M8Cm8Sk7eMetK7FkAIyO/tWxzk6SAp8wIJOahuWWTcsWVJQjPpTXDMC6lRtqB8GUBmwCMkigVkR2sbw2wibqDhTknI7cmpSryOUB2DH51GzkFSmWY8c+lRpI3mFQTjuTzStYtJljGI8+YWcHGPSotxjZyFDM4wdw6UrBTGzNjA4B6YpgV0wHUEsKYhrEH5T8hA6qetMb74YEbRxjpQAOgUlhnIznNRyyIULMuSOgB60mUh5UFWZQVcnpVfcSeA20d8dDVZ7yZkKbjt69OtOj+ZQpDA9SO2KTZfLYtNl8NgHrimMGwAQAOtRCUea2DlOh46Ujkq4w52nuakXUHLuxJwqrSCRnZi4UL0yFpkrDyRl+ScEA0gZvMCnO1eTnvUlDmQBsZ4xxg9acwYxAD7gPXpzUfzByyZ2npuqbDEBN23J/A09BiorKx3DkcDB71NGCGbewLHk4qCNlChXbHJJPUmnx4VnRWxGTgn1pWQFvAwGwMnpUikkEDgZzzUUTKgJkU7z046VIZVD7WfgjtzimSRq4T5c5fqDxSTyBFU5AU/3eeaUFWIViEjzkECoZoYxOpimZkYfOu3+VCVi00SyOPLDfNyPxFR5Mh8tB19e9OJJ2B+Sp2jYe1NmXYx6kH5R6ik11En0GMwWTClsH19RUrsjbSiGO4Xvztb2xTMfJtdVCq2R6n2qSIsGyfmLcAN6+1OEuVjeoIQMsxIkH3RzjNPZ8D5ijbm5JFTT27riTYF45zxmqaPCqkNktnK56Gk48r1EnfUsiQtMEkdQTjkHpQj8srMNmeKruYyoKLgDsR3ocqFLDCsvHHf8ACk7IdiwH37lVs7QSAOMU2F1JjCrkngn1P0qurnY0pQMORg9qchMiIdm3qQc4/KkmxW0JtzK204DhsgAcU1zuwfMAI6DHXmnTFjGhwMvwx75qug+Yh8Fl7g0+W24kTEkP85Ql+S3YGlV3LFTIeOQxOBVb7pKscgn0zj2pWkUswVgo75609h2LAkjeQEkgYOXPrUQwu3ahY+pHaoTjCnLGNjxz/OkLsX+UkLn+E9qLitYBuCNlmyT0A4PtTZmCu2RtIHGO1RvIp6uCwPC+tV8kLtX+PnHX9aCrFiPGQWclz146UM0e1MHaufy/GoQ2Y2AGFzggnqaU4I2g/dXk9BTCw1pA6sSWy3TaOAKaYwFjB4Gck+tRDzHn3bgwcn7tSybmiBbp0wT0pDZFON7FivTAU57VCwJIYvnd/COKkMqCUrtZwemf6VFKxdXViqgd+9NITIZOGKkfd689fpUUhIA7HsSeBT42d3JGNuMlcdBUdyyhiFO5R69KfKJsrSSKCSTuZuCSeD71BKxckgfd6GpZgBtG0FcYXjk1XZgxZQSQB/DQkJiSHMbEKfvAeigntn1pl3tUIqiQSgYkVlwVP88fWroaK8sILc3cVs0LuWSUELJuP3sjuOnNV9auopZIljlM3lRCJpmGDIck8ew6c1XLoZuZ6k+eNxDEcEUb8qRkqmO9RLJ5bnLYz7daSSRfKUNyT1B6VRIKytnZnrzzxSGQFlJPtx2qOVxg4ATjhaYpPlsP4vXvSuOxI7IzAbiB1BNIFJjLgcZ4NMZ1+TaxJx94jpTFlbqo+QH1oAlkkEmC6FAPTp9aYznhd5L9hUe53DFlGDxmkaRvLUM3T5eO9FxDiVLZGV4wTnnNI+15AoAAHrxTZCoRVO0g8+9BOI8EKVzwM80mVciKnLMwGzOQQP5U0uuN2/BPGKJXIcJ5TdPlHpSA4A2cyHqCKkdxS5woQZGMdKjYM2Cc+w9abI3Qs20n0FNbbnJLAY6k0hoSVBsOWKgng06JtwVXXnpmmbgYg0koIHanQOm7DklMcDvmgqxOGYOw3fKAaYzZUNxvPbPSqzl5rtIUBG5/mK9gOtVreZzcMULCLJ2kjrzxR0uWkaeQoG9VOOAKlEpDBZFCkd8VEGRUy7MHPHJp8e0EZBbjt3pNdCSdDt2tINxxjk1JDtkJGQp69OR7VCp/iXACnPNPMmyQDbhW6EjOKAHscAYUhR1pGIzuXIXtilLHiPO4Y4Y805Y2UhhwD+lAIhLEEq4ypHYc0+NiYiCQeejcmmEKNpUnHX6/hT/vOuORjp70N2HZCttYAtIeOgYU0OSVHzMV7j+VI0kpciMKD0y3FRljgLlQVOOnFJO4y8khl3owyMcA81RZCUKs21V6KKmjQlchcEjPoPqKkRAxXy4lYnvmqs5bkJ8uxBIjh+VGEAPynt71CXxLlBtDevap3TqsaSsD1wehqqRjch357YGQD3HNJxLQ+RyNyIM9eVPB9qVJ25QLlfQnn61AzNhTk+UrfXFKpXzMgEtnkk8Uh2Ltmyjf5g5bt71K6feffx0xj+Q71UXykywJ3HgAev1qd57hHiCKVRRwR+uM1rGzjZmUtxku6JwABuP3fQ+1Rq37wtkZORjsPWq98dq4UkoGOGbJz61XSXeu0klgfu9qiWjsapaGjG6oWXch3fKB61HJlWILbSODgdarlgxQ7VBwec9aPNJjONvB9SCKCBrMUKHaqg87s5PtUDFjzvBJOBgcCnB0bJK7eg3Y+8aGYrt8rJccZ4wKCrgkiqWEYDpjgt1+godt5UKdjD05qIBeQ7gyA9+30qJ3MbZLrwMZ6/pSsNak4KxgmXBbsAcAigTK20jaV6A96w777RNdxzLKojB6Y9qvW771XhiQMAAYz71UddCpJJXLR2uGGFG05JByTntTJI0MrKMAEZC55HFDsPnXdsUAADGM1HJLtEYJ6HI6devWrUUZNkMqBSQikAAc46mqoceUxbJJOQO31qzLcblUNxyd3PVu/wCHSq7yeXleq457flT5UTzFaaQFQwzz1+aoZVHOwEKMHr2p7yfI2WXn5cVA8qo6HywwGCyt0OP8al6ktmxaNc/2XbjTp4IW3N5pZkDE5469u1Y+ryXbzKL+RJJCuVZWUrjn0qeTUoGDk6XYcngYbn171n6rMkxjkFvBbrjASLOD7/Wn0M+p6q0oIJI3MeOaSJzKhKfw1VaTLltwwOgPJoaT95tVD5h7UNmti07kLuJBfPekd23FnAyw4UVVWXPBUjHp604St5W5QAw4OaNxWsPWR1G7IIzgDHSh2CjGAc9SO1V2cCQqxLccVNj90c8r29TSVxNCs+5P9Ydo6AdzUcs6gB1ChhwB1Jprh2x/CcdTUIUBnwG3j+I9AKTbGkiwo4w3+8eKHIDhlGdw4A7VCz9Sr5X3HWogwBLKHI5yRxRsFiQSbH35Oc4Jz/KkEnI2EhieW9qrlsqBuG3PAxU5l2oyM4BYfxcVKKsJI2Dujm5U4AAzj60bmBfzFWQL1IOBUKsCgCrg/wA6ONwAXp1GapDsI2xkIzye2KcgzCXcZVSOB1JqIuMFuN569gKdgbn3DA4x70uo7kiThS5jJjdeBkZ4qL+M7W4fHCjGD/SljPmyMEGBjOT2pwByoJBTOfTmi+gyZV3ZJGR0JzzVlCF+YF+mAMVVR1yu4YweKnUnG8nO4/e60hEuU2javJOd1SEAj5FbzGOMk1CrKWAZiSO/b6U8EDCoPmx1PFAD9yhmAUjsFH86l81mAU4YjkL/AI1EgdkCD5j12+lLwkrliAx4PGMUALNnHLcE54/xphAO0xq25epBprSb8DO4jr6U5gyIpLBAB1XpjvSaGMLqoI+VwOcEc5podwxZchSejdvpS/KFZsjafXr9aiLnBb723pSWhSNJJQ0LZ4jjOSCBzn1qHcbiN1RzG+0hgDjIqta34QqWtYp1GSY5c7WHvjmnoyLvnjzbBzxGnIJ9BntW0bNJ3Ity7kxgWG0Ox5FCEcldpJ/rVUSLNAx2KTn7x+vTFMndp5PmbYQTzu4x24qAFVJKg5XJJBzk0pb6bFepNOykYAGMZKDOCfaoY8KNyjKg8gmnK6tIFQspAyMnPWo2IDbHYB/vA5/nUMLkhcgGMRAmTBG7qPpU5uNihVbL7cEg/piqQIcn5Srk8YPQU0sHi2sclDwQMFqd2hNFmVg0eG3GUcAVGSEkyXAZRgk+tQbmEZCJznlqbhR8wAfjPoeaQImaRWPynPXn/H2prybVDKoYrxg8/p6VBlsIcd8YHU0wbuRJgHHB9KB7ErshGWJKD+Efwn0qPeW+ULgs3TNRSgksu/cucnnGBTJWYK7KpIbo2ehoAmaRTsViCFPQDH51E+DkuwLD5jj19KrmXZtJQqCOTnr/APWpElXOGyVAJUAcUw2HL8vKbslcnPH4U6OXyWByy7f4h1FQGU7AzA7sfe6fQU0uSWy3zY+b39qa12JbLPmYXLFgSSQM9fxphl2iMsFZt2Tz/OqjTkIy8ZJx05H+FLvKNnCsFHOOlWTcnbJYqWXg9QP0pmc7vmAK/dU96hY/KCCvTP3sYqvNOixod6L3yR09zTuS3YJTgYChvWqxJdnkxuQA9T61Uu77dISH3c/eB61UeYtyCCOuM44qXEm5cJLLtj3EEiMAclj6D3p1+Y4rdYmtpo71QFfzW/p24qxYajEllFIgnM1qkrLAkZKl34EhbtgZ61l6teRvLawh5Z/s8IjeVwQznJPfnvgVSjoRzanqsiqdyKAWb0pFA2DKjcOC2ai8zCqSMEenXFNVmUZKAjPy1Fu5uyw3UgEBc5xjrT4c7QIyS+TkHoKq+YTLu3Yf/Z6CnNKjS4TcDjOT0NNKwtSwrc5x83vT2O6Fcljz93tiqYkAOSpBPQetPM+FWNwEI7k9aBMkdi7ooZVHQE9qizJIxADM7fxDoaRcysWGWHSpjLsbYpJGMZXjB+tUoXFewhO0qxAO3+E9Kryk/aMyYdyONvapJZFhj+zM29gMhl5Ge9QplSDll9SKU1ZhHuMkmVQScl+M8cUkrh5A25cYxuH8qegzFliSgyfrTYlTLBiNoG7b70kWmOICMRsZfl4z3puULFgCOOQepNBcA5GCucHPP5UrtjIjAOT1zSYDWlwwAyBxnPc08yPIu5sf7IP8qgOUGAp3HkkdfxpyEBCynOODvHFSMm2mWRQIsYPY0i4IOGy/X/8AVQh9AHGM5FNVvMZQNsZAwOKTGmTqWYLt3F+28ZAFWUlVDhVVn9z+tVcnbgMoUd+mRSLl5g6DCnA9aA3LkLjbgFSW5x3zmncySkFfnPU9elVyQpBXBCnlQealTqGACk+hz+NADxKcglcn+IelO3gZOCBjHTP4VBvBYnBXPcc5+tKx6FecdSD1/wAKAJ/kyGJKnoM0k5+UqWYAYIx0GarNKSueATwOc80inaPmUnPUCgdiRhh/LA3HggEf4U0sC2WKoAMYbnn0psgAIwCrk8AnHFRxrk8qrAHPH8qVhoMovKnJB6EVLyHb5duRnLdB9Kjl4QjO3achSOTUO8swKgsh7ZprQLXJDkMrFlckdA36U1F3SMnljcegDY5qN32Abgp3EcryRTA7bGAKkDv3JouOxIylQVbJI9OxqJuOGJIPsOTT/MZo9o2hfUckexqDBYjbncRz7UtwQ98MSdzeZ247Ux5GUK7Mwx2HHHtUT7tpwvQZbc2fxpm9VR9zcYB3Dk0wJJH3E4bKjlucA59aVJQZHZX25zgKMjHvUAZTGG3LgNgDqT9aQyYWXGwk9f8AZPtRa4WLMYPlhQQcHqO9QFwN5DYwehHJNRln6cFhkHbTNxKgAA8jA7n60hWFkJ4JK9c59T/hSrIpaTcQVAPFN3hUJJC/3uP0qGZ2Y4I+YkYAHWmS2Kzb0BU455zxUbN8/qT0I7Uwu6HIbD+n938KYrfeBbCqM/N3NVYTZKJPlbI/2VY8496iZiGIddrIegHWoWcg8DOOfakaZmfG0An0OBiqSRDYruQGI2kk8E9/pTpZ9u/I2cAEA1WMmMLlCM9Qailk2FmJx2FMi5aeYqjsjLgDq1c7e3EshO0goPwrQvmDxnZkvnGAen+NZwjkkcADGeuBxVpE36lJvO++B8vY96aJJWI+UY7mtNV/dyFXiYx9fWq89xIRgJGOxwOta8vcyubmizGbTlgiuYotsU6TRPIE8xmHyNz1Hb2qlqhQvah50mmggWOWZTkOwJ4B74GBmrNqZl0O0ey06C+fe4lYwCRoznhSP1zTtYjV7K486ytrZobZJW8pcGGYtjYT3yOcdqdkRc7dZjjJyQR1PrUiSFwMZKnjHeqKydTk55zgfdNCSBIw7M25jzz1rlvc7jVhTYVJAPGdoHNJNIsp2jO/HA7D8az1uZHkypGB1525NOEmRuc5zzvz0q+hPUmYDYQDwD1J5pxiaX7wBPByDn8MVVaT5SCuSeQ3qPpToZthYglGP3SKEtdRtscZyo3QLIMP8x+7n2AqaW8clwuVGMAdfxqkZSxBZjxxwDhqRQw+UbSD3ByR7Uc99EFr6k8bsXyGw2MZJxmnpM2DvY/NwBnvVZ2LscneVHGaUMG5bkjsOOajyHYlVhhk5GCaepCrhjwDwQMEUxZPkEZ4IySxHWhi7ngbww7UbDJDlOQCzEcn37UzfkjOBgY6Y5p/JCBA24Hn2phcbRhBgDHJyTmiwXLEZYsDjqfvDv8AjTZ2BaQ4VQ3AB7etQmZ0KwAJgHJcjJI/pTZJQThCGB+aqktBLclVlYADHfGOamjLLyeDnbjjiqzSEui7VwBn5e9IHKDBYb+mMZFZsovMgwyR7WBPPNNAB+ZNwUdef1quDhiM4AHT3qTeGUKUKjHRec1IyddoG5uvuRTguAWLAZ6A8VGnlqodiAv3cHqKjL/J8p3YJwCelA0i6GAiZGGDwCw5x+NMZggzgYJ/yarCVlGSw3Z5FOJDfKNpzyMdqLgSAh2w4XAz92nlmwACgGMcHrUURIZlUDc3BGeaAV/iKjI5wKLDG7xkcb/XLdalEgAOexwCewqFpAy7VjCYPXOMn1pAwVvLYhgOBQAPIfNAGxiSeKiduFGBx820DnP1pwYbyrY298c/rSAg5YZPGeBjNAERcKCWCknjjnFIZFCqOuT0B6fhTnbjeMAqOMCq43srEdhye9IdyUssjDO4gnkdz9KimlVguxmDDg8YGKcobamBkquTgYP1pqRNLI2Wwf7x7j0phdEeUZEIGW5BPNQlsQ52g/7PXPvU0kLBMKXwD065qGRWT5Nr5A3EE44+tGpNyFlKv/dDnpT8KEY4+YHkkYA+lNEiFnDtnkZ+noDUiXEH71n+YKNqr61cFdilLQgaZlYYByex4zUZlLybgBuzk44FClVTc5BYjGCO1NyASOvU7j2FHKLmHeZ0Kj/gLVGZBlsnryCBSMRgdWxjjGBUbuoO7sAQT2/CnYi495AMY6g4BqJyPkZWAOeo5prZAXAHOev86iY5wCxA+v60MnmBpTvzGDwckntTHbcDno3fvxTWYhl24z2HSomzt56EZDDuaauS2K0wBHHA+XJqs8pctgtgdBUjKe3Ixzn+lQEZOCCDjIz1qoom4x5GPzFgzD1HNNe4LRSRuAd643egpqrknJx35pwiLNhFzk8cda1iiJMrZO1VT5UHHFQnjpzVuVfL5brn1zVIsoOX/IVRNzpNFt7RLe1MkM81xcpMwdJmjUbOicdScVia95O60mtIjb29zCJRGzlmLZIJOepz0PpV9LqG00i0aWe9AllaRFttoETLxkk/xH+VZGq3Ud/eecklzLlNpa427gR2G3gCq2Mmz0YO27K4yRkY70FlMyKC2MZ9cGqoZiqAOwAPU/1o8wK4KduN3TmuZJI77l9GUIxZQNvTpzTGkJk5IzjkY4NVS5Pyk5J4x/gakGXOEGWHBy3WhgmTqxQgAHeBwc04y5QqwI/hyexqCIlyVwFDYxkU4MASBjAOMkcD3oGTsy7U+8+OSM4pVOIwd4xnHXp70xWViccKB97HX6U4uMDeVBUAdOvvStbUB6kYwQWOfvA1KyEuu51ZQOCOgqFFwxOSrAZPGAadDKTGChDL0OecUmh3JIyQoQgsB0A7g+hpQ3lsNwxxjAOKY7lc4OBjgjmmyFiqgYyMEsDnj/GlZhcnlkDZwSGNQnO1QoUAfxU1ZQ2VBIPXdikeYkA5yegI4B9qLACE5YZJYevpUkeNuGXgfxKKicnq+P6n2oV/lG3btA7fyoaYXJkB8wuVKr7GpARl1BA/n+FQCXcSFAXHVT6UrPnaOfX2H40mh3JWdPmULweD35pAX3EDJwMcfSo8ruJyBx8xHajeVXcCd3XI9KlrUq5YBXIyp3dyx6ZqUY3YJLEjIJHSq0nOEDAKBwx596PMYqfm25Hc5osF2WmcA4fjd0yOn0pofayKCeOoxwDVUs21Tkl+gx2FSQljt3ZBycEHFCGSZfJPG44PX+VS+ZlQXHJOTk9qrFihxlVB4yKUqR8xPToAP507Bcm2l/mCkIRx2PFNLg5LMc9OeM1CCVkLNkqPzzR5uGLM2Nx4Axyf6UWQXHN90rzgZ6DpURYtswR8vpwR7GiRiFYgqAT1680wyDaOdvHPuaTQ7iE7Ny/xngBRnj60EAkkY3AcnsaY7YbCbsAZ44zTUY7t/Ax0FKwE8oYAHI+f+EdqEkIUsGJXb9Bn3qvuYkmNgQxOGB5OKaZT5h6MoHJPpTQuhY+1SGQbcgdAxqrKQZDxjI6Z4pvKqV+XJ6n1z/KmE4lGTlAM/UCq1tqSRnO5iCTjoAM0HCLzgE9M8/pSo4Gd2QDwNvH4UyRg+F245zn0pRYnqJLLtzhPvcj+tQOx3/LkKecnvTmbB3EEBvTvUTbScZG3H61TYrAWz9AcEe9RqSF5GSD0x0pxO3lmz6np+dQsWwD1OMdfyoukQwkcZzGeD61G7AEHJz6UMRhQeW+v6UwZAbDYwcE9sU0yWBlyxwow3BJGcUwOSxAxzwMdAKcqjkZz/FzxSEgxYc8dgKtEkRyU56DpjvUbMXUbiMjv3qcozZZRgZOD6CqM7gYRSDjsOwppaktiGQA4PIHQmkF4cgZKjHUDn86hbLDbj3qPbhSOma1WhDdx1xOzAqOFP61VZQW61M3AweoqOJgkqMyCRVbJVujD0NNkm9p8twuh26adf2VpIHcypKy7pDnhjkHtxWNrrXJuFN5dQXLhOHhYEAZPHAHNaCalZDJOi2IP1f8AxrG1W6S6mDwW0NsoGCkecE+vPersZM78HIyckdsH+lOU7W5+6G5z3/CmodxUcHAzkdacCGXLElyeh6muU7kPUL1xuUnjnpjpRFy4Uj1GT2qNZCqKGjIYdPerCMhC/MxDfe+XpRa47hG3y7X5C++T/wDqqSNjliW+Q8kgZ6UsCqzNvUHHzZ6ZoUhQflHGQTnP44p8rBMXzS2wnnDdQev4UCTJOVAUnkA8CneWgOBwx7E8k0xkKgqu7HVgRn9abiw5g2EnO5SOvLdvxpfO2HCr15G6omAMgxhh9KFYBgW+XqBzwamw0yYSl/Qe6gcmnKzOBgHjrzjiolCA4ZfbNSbF4KtgD1NFhkh2hQcjcece1IGMa7du4n1PAqNNw3oR1YkdxmrIUhURicHrg8fnRYZC4LBNpwScbSOnvTggLAjIHrjOPelwAT6j1JpVIIw3A6nNJjGkMDtYlsCn7BgFT34Bp6qp2lGPPUYpyxl+49PTFZ7jIyAzZ3AADkjg05T8xG0ZAx7H3pZl2HaTuPsc0D7xDADjoetAwABCqAQSfvUsoJXPYccGnkg/dA9vamkEpyQeh4NAIbGxODtA7HJ60p+TjJB7D3o2qMEg7v0AqENiUbScfdDZzQBKq/MQp+Uf3ucmpGRlIO7IK568VXyF+ZQT2I9acJ5GyQoOD8vy047gI2cc8fxYxnmmE5JLN82PTrTXc87QF5yOM0GT5CAFA6njk/Sm4pjuBJ8sZwTtxtFDy85ZD8pxjGCKiLMhwJP06fWkl82Rd+GKAfMaXKFxRLkggEkdd3ejzB8vP3hzUBdm7fLnIx6UzOGOMFV69hSsFyXerM2wkBicY7VLGkkrLzuYnAA6GqZk6PnJYclfWnC6kG6NeVz+f49qSWomyxKWQ7WK7lyODx+JqF8nGQSWIzk/ypHkUhWVSsnTr+lMW4ZeFTkHK5OcfWrsRzDnLDL7V687h0/CoAzJuBOR3Gepp0tw7MGACADuM59aiklMu5gueckHjihqNxXYjOCAOAVBP09qiYgtgADpz2FMdm5bOSO9RsSxJfrjPtn1qWIcxTlixIzgf/XqORgm71Ppzmg7iuCcheQcVGx3OWOeO570EsHcZO0DHY08XXl4CquB2PJNVpAQ+F9OaAR1IGORWidhMWSZmDHKgvyR7VCZCMc55yRUm4BSdpPFQOxZOAOnBFO5LGvI2Cm98emaiACtlT7EVIvJBI/GmnGM4PIrSOhDIyxwC3SoyudwycdqndDhSo47VXcnccdKq5LI3JINMRkWVDIu9AQWXONw9M9qVzgmoSMnAqiTobO1jvoGmtNBZoskBmvSoOOuM9cVia/afY7xIzai0JQM0Qm838Se30rQsr6OK1sWminZbdpbeQquUZJAeh/vD071T1vy45re0jWcm1hELSTpsdzknkdgAcCnczZ3EauAxL/L13Yx+fpUzWzhULEqwPBxn8KhjuCnEqEgccDBH405rxmZCqjdzljyaySR2N3FKNGxz94Dv/jQjYYEAqoGMj1qFmY4bcRn/ZPNKN65b72eQT2qXuCLSSIcEs2QMEAUjSeYgQqzDHBzg/8A1qrJufOCM+vtU6cnK5OOBz3ouOw8TzCRgCG7cgHNJJJI+TcEgYxt70AY4f5uMAk809CoGVHK+2cUNsrlGxYOx2AAU9j19yakSIfvG3Eqp79D+NImMtg5yO3T6VOpkOAqkIeoJGDSuOwkSMRtLfNnO3+uacE2gBmAHWnRGXb9xAvqOcfjTwEAG7GAMY3UrlJAUVRwQuRk46fnQigIRuA9sU4EZbb8o/n71K0Y+Zix45zyMj8qm4yILzg4JznJ6UMGIDDcrH5VA9KlVCwLAEj0HBxSA8lo1AGNvJOT9KLhYjMahflyxA96RY2UDdtIPIz3/wAKlPygBNxA+91xmkwMMzYyDggdqgojETh2wQTnGakUPkAqVZTjGacAeyrnpSDI2sR8xzzRcBI1JBLHCg9qUuG6PtwMbcYzT0WIfeBVF6leppZJVcNzjjCnOfzouBCONq/KT/sntTHIwBgkA5IBpXVN4JAORwRTZGOxVOeDwMUAMVwwPG0fqD2psZ27wxI5wT2ApzEgEEE4qFlHJbHqQxxQnYY4gEMEZNwPGeCfpQwCKuWGccZPemPlsbVBJyMrwRUUhBVuSDnjjPNXe4mEjLg7SW5zketNcEggt74z96o2wgJ53D1NI8mOMgHgA9jRsIkOVb5iDgcg8VFhG3DJ9OOg96RrhiDg59eOc1AGATBPfr0yaCXJFhX7FflHTHeo9jEnjGe3pUSyZUKqnCnOM8D3oMkvLBjkgHPfiloTzDiTnLH5geMcdqjd3Y8Z5656GmlmyWXJHcnt7mo3YhmUEAnqQabFceWLd8joD6VGZGKgcfLx/n1pj8SbTlWB/A0EgDdtwudrDPU+opbiuOb7uAwGT8oJ/SmMxIZgCT3GOgpsjjaDg8Z9qaWwp7HjJ7UWQrivkqCz7QR0qN9hAO/lj0ApcAAgcAHk9qaQy7fkAB5A9KaQCBVbuFYc59vSlIjD9OMdT60zGCCTk+gp6QSSl2VCSOeemKpIkjkAKqM/d6Y6YqLOFIPrke9WY4VGSzYHTrVWQfMQOB/KqS6ivYazHcCBj1oV0QDcu7PTNIcj6Dg1Ez547Dp2qlZEsSeQuRgkAdhVUnaTjJJqVjgZqMcnnp61QmyJvXvTFUt069qlZcZAGTS27PFMkqOUdCGUjqCOhoS1IL6RxX2kWtu939jkt3c4eNmjkDHO7K/xDpzVXWpklltY4pJJlt4REZ5FKtKck5wecDOBWzb3j22lwSzave2pndysMMQcHnluvc1W1q2FxH9pGpzXsqQCcedHt3RFsEqc9QeoNaNGbZ1wtolRj9oTA+UFehx3FNlEcZAhKycc7lPWoNvO44B68CpIbcyEksUB5JHWsOa+yO1RYskyKMLE4OO7d6iD7MEjvwc5qybSMfxZYDO3PSlVoY8qUbPc1LbuUkQKu8DIIxycDrU0ZIGFHC9ac0iuo2I/Pq2MCmk5+YlAM9M5/Spcl1K5RwORkqwX0IoKDhwrD1B4H1pQxcENInJGcfdqVfLUlc7hnjB/zxS51caiMjZsZVEY+mNwHrxUm3kE79oPbNTgqxGAoGc4Zj/KnL8/JJAz0UZx+dJyKUSJVcKwKcn16D2p0av1I78kLUqJvJRRISTgZwKnjQEA4bjj74o5mx8pCq/wySMVAznPanJ5TFsZ3EYUlyQaslYFEZdyW6Fcjp9auOdM8n9y83mg8kuMfkKqMb6tkyduhn4RgCCePvcGmmI8ZySeeTn+tWvOgIVjM5xgcDn8aGnjVi+8hRypMfI96Q0RRANKAZBEeh45FR4xOcElt2M92p8lwAvynPPA8vrR56Bl3ED1O3vUsdmNFvKzHAcKeCBzz6VE6EOAyu2Dj5avx6kmCWKEtwMjFKXtwoMr5k5IAP3aLINV0M44DL8zcHoR1oJXYNjq3fGOtSSyJlTE455+YdKjlnj27REhKnsvWoui7DckgM/y5BUYqs7bB1Q8cipJJQc/IqjoBt6VGZUXgMg/Wi9xWGO0mQSylWxx/KothILDauOpPepGKhmPmRjAxnbxTN672LPHjA7U15gRFmDekn8qR+hzn6dKDhi25unOMUGYZKYXjuQeKpMlkZ3bP3atnr1H5mmuoC/NuznPTpTlBJPTnv0pqfLljggnk0epI1wzhW39fT0qFUOSAOB78/WrkKIRjgc9/SrOy3jjLIpIzg/X39qtK6uRIy1jk2gKp56ZPWnxQ3ATeYvl69O9Wlfgq3T1A7UjzuiuIpH6YINOL7ktFUic4HlqQMgZOKrTxy7HJXDN7jmp3k3ttLOAAAQe9QSyE52HJ9+x9qbsyGVmz8qBST0z7ehpZG4YsoCjg0rK4B4Uj1/xqN43VjvXHf1FSMZuJVeSSc5FIsgz9wYHOKMZbGGAJ45pqAsrEdqa8guAdtgOeMnj0FPjXcBub73bNRszcbR1GM+1NOUwCMOOtFrCuWCiRt/rO2eBmla5YRsqttQj8TVdQRyCM+lMIUH5iQR696dxDsrHGQPvfnULnnOefSnthWJIzmoeN5AB9RQri0EIJ6n5T1qNl57Ypyg45HPrULsWbkn8K10JBl6n9PSopGA+71pcnJIoEYzliAO9AiPr60x8jucVI5AJA6dqjOapEs3bAqmmRf2m1l9jLt5C3Ebu+f4tu3nbn1qnrd1c25ljf7M0dzEgilgXC+SDwqegz175pkF9atZxW2o200ohLGKSGQIwB5KnIwRnmoNbkaX7GwiWC28gfZ4g24hNx5J9Sc1aM2dvuZeQQTjpip0lk+XL8EcDb+lVAkx4CJkcjJqQJMz4+QA+mTzXFznoJEvmMWODtPoSKVwWzxx0yH71D9nbjLM3Y4GBTo7UGQgnJB6FqlzK5dSRPKVlAMeCehJNSrNCh4dRxg7RSwW0SqRhj6YHT3qVREjA/MUHY+lSzRRH/aLcKAA5OOgHy01pnGMFlUnCjI5qREiXaDzkfdqeG4kinLRLGCRgB+QvFK6KsV2R1VQQS2OpY8VKkUMgyzjaB2zzVhXdo1z8wHOAeBRjgZzjPQNSb1Gh8Ftp7KWlkkRwfl+U1MsdoqAxZOTjG0/nUUcJJyGVscnc1SoMrgvgD3P4VXNdEtC7Ydy4VOOo2dqbiLgeWAR/dUirCBdq85464qcbMpvYtt7j+lCbYmUldAPl3gkYAwc1IWwPklI/vb+Rip5Ps24kFxKT90Dr+NCuhVVIPcZxkVT0AhWYgjdJGT05FMaWSRgU8lWHYcA1YJQZCgfU1E0Q3bfLDFe1TzAV5YnVDL5kXB4A681A6FiFEpJ4PzL1qdoTuBVFHrg0xl+bIVc9fX8KiRaQnlu21m2Db2YDikMch5DqCR1AHSp3iL7dqoBjJ5qJhlGYRj5Tjjgn6UAiCRZ0wS6sOvQVWlaUtkjr6DpV2VQF4jDD13VVkyN77ANvc/0pjKmflIMQyeT1pJWDMM2+DjPBzwKtog3ZCgkdd2RTPIVfl4ZuuSOSPamnZCauUJCrkHyyqke9RkW4jIIYt0zkjmtFEUlgIsgEexzUb26iTJRynqaexBmFYjgKz5xyN3So5QgG1JSv07VfaJQrDYMEceuKasIKjKkYGeR+lHMJxuZjvjhZuT6ZpxvJhwZEYHgjB6VdkQMGZ0OT0Pao1g/dkbRgjr6UKbRDp3KxumwSWUKOmBUcd2pUhpNueuRwa0YLYMihgM4yM8/pUl5ZRREJGSTgEgjBzWibauQ4PuZiGORmbz40UcnOQTT0nti5VXUhTnce9OZVTJIyT2Jqu6r5uPLIX39afPYnkaJJbyJSAsyEHjkVBLdQlQFk4zyVGKifYT8sQB6UrISVBTbgcjFHOhNEcl0m8BQTUZkGByOT+IqR024YIM57ntRsXJzg57UNisReZnCntzn1pGl8zknBbrUjKuNy4znHtTSQOuBjqPWqTuLQazBeOQT6VC0gOd2RjpUkkgZwTgA8YqIyJj5lz9KpbahcaX5yc5prFjyoNORgQeDmkGRnKtmmhMiO4Agng0zbgc5qwwbZgCoyCF5qkiWQ5GMCmN3qwkQJznj3prgLVJElfb/epY9hlXzt3lbhu2dcd8e9Nbk8fSnxxl2VcqNxABY4A+p7U0iWXZF0PnadVI+kdUdbuLe4a0jsfOEUEPlZmA3H5ic8cd6059DvoSYnazjYfwtdICP1rGv7aSwuFS4aJnK7h5UgcfmKtRW5m2ejjYXKhR05JpYy7gEDGBwAeSaZtTbgeX+XNLEMfMgw3bBx+dea2eukTRRO4JLKp6jJOPxqw1o235mUHaDyp596rjzlIAP1HY09ZpVGBkk9RQpR6oOViiFt2VbAGSSR1qQo6jBZiOuCOTUkZY8Mny5Bq7HHG5J48wjJGOB7ZqGrl7FHzSPnIIXsB/Opwd2SWbaPX9K1IwBsESxNgclVzx6YqWVF+0ZkjVPUIMAVp7PTcnn8jLiRi5x1IxVmOFtoUsOex6qalYeWnykFOpIp3zNIHCttU/Kaiw73QiQENhhgg44qQxXDqF8stnkfSnj55DnjYCdxHf0qUyyBFdWYAdFP+NVFIhthBBIwbci4IxkLjNRSIMbh1HGBx3qyl3MwGcCPBGD0qQRwlT55ZFB5Krnr7VXLfRCV+pm7SGOWYkd+pHrUiLs4P3R27n6VNKYzIrBy4XjA4OPekwgbGGXAypFTYdyGNeTknBPbmlCiR/vHYpx0wcUuAQ7RsNo5yPWnLGAy8fNwRzwRRaw7kUkOG5DbTyM96jki2srDqF+7jt6irfzA4UKCeRjvS7S0gC4O32/SjlC5Vht1fBZGBI6jg1ZtNNMoZi+MdcjPFAl2A55boW4q0t2sSfLnHZicHP0qoxj1Ik30Ks2lQxW8dz5svkO2AAo3N6n2qF9MtDb74Z2aQjJVjzsPfFXbi7+1KgeRgFbOB8uD/Ws+UosRwwBDcjqT/hWl4rZCXM92UpLfPOOQB97rUDxCRmUHH07GriyAx7ckhjnPXFVxuJ47cKeM/WsHZmqTIRGEUMTj+EnPT0JqBsqCzOc5BJ9varRkXOJFGF7f1ppX5ABjyz09hSuOxWK7WwGbC/NuPTBqu5Ykbm3bifmzwDVySOIpiRvkz09frVRlRFGVyPTHFIFqVph820/cznHqaiYgM21WAIyMdKnkC5ZVGV6+4xUDEOzBQRGR0zQDQ3zWXa2GAAxgdqjeWSQHczHnueRUh3bOSBk+nU1GUGS56L1ApxIZGuTG5JUn1FV5Xbd8qqGJxz3qbGDyWKnr7ChQqxsm3Mh6MTVEOJVCyZIQhfUEU94XIxJL16fSnbMHgZY5780kitnK8gfrVKRnyldoVH3HYjoM9qjMeON7HPGRVoxvuXaoweRzULBtvOcZ4xV3JsQCCMBclufekWJMNwT9T2qcWkkhJXAA96sfYCkO+WTaGHT1pxTYmrGf5acErj0oyvGRgfSnvDGvAYkCmFFz8uOvSnYVgd0YAKMEHnNMZsAnv3oKkO2FJApjAjOOc+tXF6EtDCScknApkhwCB1qQg/ePPtUTDHPUVVyWiJskZyc00nPBp74HTrULN607iYrKKURO+1FyzNwFA6n0qMsAefwpJJS+AMg9sda0JbLd3p+qXAjEthdSGJPLUmE5CjoCcc4rJvra4tX8u6geBiMgOu0ketdFeWet3flPKvkyhArFrkI8mOhKk9ccVz2pRXMFw0N8JFmX+GQ5OO3PpTijJnqMcZxu+Xk46U5kkyvC85x/9ekVTu3DgDHJqVcopYsSxPXFeXc9tREA6AqSxHO2pApHzgEswwfWkkIxyec9Ae9TrGEj5fnHUcg1I7WBU2oynhz6elSgMzCNwyt0yOKfFvEy/dPHT39aleJkLkncuccU0BFhlYlCykHkVOGdmwd2MZ46EVNGoVQWCg4wcnOfpUjBAiKWABJ4HUU9RXQxiAgTBPq2P0qUbkXBYHJ4yckGpIgACD82Bjdj9ackSOThs45xkDP40WZDfQao/dKATkAgEdqcpLYVwdijg4pVRVUjcQ5PQHmpAqn5SzFwM5A4qrCGmNWAMWQP4TnpSJtZMgkE9SGJz9RUkqEqAiEsODjvUIUK5wrKMbe/5Z9KYJj/ACwxZEUdMnafzqZLZ5SiwN9AWHNVFIXeyEB15AJ6/SlYs7YBx6c9KatuxO4wI6Ssdyjaf4SME96nRgxIOEBHXvVR3CODIpYEHODzxSo/yNv5x0PqaTepTdya4Z4ijZjbHHH9ailZ1G7OM/P1pVnAIfrgd+xqtNc+ZkM2GBzyKTegkWQMruRjgdAcc03AUsgHynqc5IqssmFCjg55NJndF35PyqxpXHYV2jB7tz6/zqKTBjZBkO3NMnYYwNuFIOScUxjtVAy5brjNIqyE3M0YUghjkYBxxSsw/i4OAo9RSEAqpAOV5OcZNOkIJUc+YePY0FCIGLYlYBSdufTjpUUiBCGjGVb5cHnNWCpfcOBzz7VH5SsrEMQo7UgKgk2Asw+63AamMpMoAIO7p7VaeNFBYc4OQpOaiQfMzKADjrnp70rBcrvGhk2c7h1PTNV5mVBII+hOPXmrMkW8qSAeze5pVs975AOT1x3+lOz6CZlycdDk45HenCPMZxke/vV+WBUyyryowxzmowInAIbaM/dNNKxLXYpFW2ELkk4x70gRSwA6AdasEAFsDB3csKjlYbnPOPUd6auSyEkHBCjOeSKYZACQoz+lPZRsJz839KBAJGwSNwHFVuQ0VpHJC/OT9ajcfNlCTnPFabW8K+VuAycncTxVN5URSDjdkgYFU1ZGZCkshG3tjntzUU5eQqpJOOgPNSFi7bupUc1GrE57r2Y00JkTqc54A9KZu2EHA3ZqWVRgc/KTimR25ZxsII6c07XC4y5nMgxx9RUIJCkYFXJIFQNvzVZlHzYBJrVRsZNkIbnn8qjncI/yjNOJBcDODUcrAcIOfWtIolshkk3HJAqLdk4Ap3PPFMAOaexIP1wKdZym2vIJwoYxOH2nocHOKQKe5p1vLHFewSTrvhSRS69cqCM0riZfvYNJmla4ku7y3M5Mm2a1LHnnhs4P1rJ1q4S4mtUhSYQQQiKKSYYaQZJ3fTJ4Fat7qrnUp7bVLkahpk53Bo23GMH7rJ/dYf3fwrM8USQw/wBnRQ3MdysdqEEiHg/Me3Y+1bRsYyPUUUyOuAyg88dDT0UHjIwe44H0NSoqHPY46j+GlWIsrMOgzn/CvKaPcUiMqpKtg7evTk/WpYuoYEKCeAe3/wBaiC2yqh51Vm5AOSQfQ1Ze0liVhKPmBGQB0PalysOZXGwFiWGfmA4we3rUsZUxnAJQD1wSfemeU6kBlJY9s8/jUiICdp49xSC6LGCmGV/lzzzVrYrOzEF1zg4ABIqqi7iAMe49vWpVO1gQWCnJ9apEMnGFj4UnB5Oe3pQHjMRyu9D0A5zSLtWRWCAJ7HvSuxidijEc4JC5yDTEODq7b4iQeAxA5AprDcxBPLc5PFLwq8MOnbinrGWz6A5JJ6e1MByASIy+ZvBHPY0oIkjZWRm/2gf0qM8k5YBs/UYqNP3bnc31PrVIVh00Q2hlYjnnPHXtUbOTnCKu3PLcZFNcshAd9wHIwetNEmZCMKQTggik9wAoNwyVJBzkDp6D3FRFf3fzE5UdQeKjZiWO5sAHBAzx9PWmIVw0eV2jr2JNTcdh5dfLXeW6E49/SoshX5BZuvXJpZSV2qw4KnqfSo5JI2m/dRn5VIO40mNE0UgYY7k5PHWmq7GRiGzgYwB+lQRsUOf4iflGPXinhsKuflznBPXNIY4xg4I5PQAjpQba5ktJW2MYocE/KPl9yaWOcoWcAMQT36VDNeyOSg+44wVzkmtI8vUWo2Itxt+XC+vJojLFyuRgZ4FMjSaRSEXjr81SmyuFIzHs3cDPTnvUKLZXMhiFwz8bW6kAdqkRBJt2s2SeT6097SRQdwIYcFd3J/8Ar1G25RnJOPlx7U+W24cyZHc2Zi3u2zOOgNVFj+Utuw2O/Y1YuPNJUZBBG3Hr/n1qBAiqyEFgBk/7J9KljvoRu+cgkbScZxjJ9KYZmCBQOp4OentUsqoykZYFeST2qtkYBbICjv0+tK4txsskhHP3+59aiaR+DhcZx9B9KeRyCCWJ7N2oTAQ5bA9D3pibsRAgydgOgXGKYQAQhJyp/OpJAinK8seRxUbgHG1SGPTJqiRCwJJAxtwMHnNRMdsjYJ5HUU4/KTuJ29/U+1RMNyDPbpjtR0Jeo395IoDbmP8AD7Uk8HlhGdh6ilR2jBUfwjNRs5fJkY9M81Sehm11Bioztx+NRM2H4HHcHpSOV8lRt685z0pXcPIu0hQBiqRLGOnygN16kUzztqMFOOajkOdxLHOeKjI3MMdcc+lUtCWSF3mOegPpUG4ify8/NVgeX5ZJcBj/AAiqjPzvGAemTW0djJi3UYiCsTlj1pitGATgHjoabJhgWBLN6U2JC7gY4PYVV7Cd2QuRvPHFNA9KtMgBKkAEGoJ8BjjtSeuoETDIOe1VpAST6fqanbr1pLO4SLULWWQZjjlVm47A0mTIbPYRwN5VzfQQXHeLazbD6MQMA+vpWNqUMltcPDcKBKOeDkEHkEHuCO9dZd25jvbGVrmWKS3ACpHC0nm/MSXjKjDb885P1rnfELJ9pghwqvEhDquD5ZLFhHkf3QQP0raBiz2dgFUEfxAZqeORlUgHIyOv1oorzkey9jX8Pxx3cV2ZkBMTjbjjFNjmfa5JyxkOSevHAoorol8EX6mEdZS+RWV2eVOcEk8jrUiY2qMc889zRRXL1NiRgEYgfxdTRH/EDyBwKKKHuNbFu0ZvlyxOTjmpYsm5MYO1B2HFFFWR1Ii7b0OexFSWR8wsWGeoxRRSW4PYkMaFjxjA7VHCo3uASAOcCiir7ErYjWNC5G0DOSaqbNyuxZsjAooqJbjQlxGoJcDDAD+VRyqEKhQBkZ6fSiilIqPQfO5OFwoDZzgVmyHaegI9O1FFW9ylsNMzRlQMHdJtOeeK0I41Oxeg6frRRUfbYnsEsaZY4GQAKbGAisVUAg+ntRRVx3ZK1J5pHSOF42KEIOlQruBZi7seOp6Zoook3zFJKxA8rqyEMctnJqBmPrjPX8qKKi5ViAk+X9GFV5RseIj+LrnvRRUMoJnZlUE8Hg+4plyAcMRzuxRRT7iZHKAW5HvUON0gBJooqepLIyM5zk4NMclgzH7xPWiiqjsIifhHI4IpmAAABxiiimZshPK57miX5UkI6gcUUU0JlaTiVaF5LE80UVS3IY6ONMDKg5PeopY1BOM454oorToQyp3I9RUMnOKKK1hsSx6gZx60pYqVIPNFFUIgdizknrUTdKKKGSiuxyefWmso6fWiiktyZFaS7uYIHihuJo4jnKLIQPyrEfjgcd6KK3W5iz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small papules with adherent scale are present in this patient with pityriasis lichenoides chronica.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25418=[""].join("\n");
var outline_f24_52_25418=null;
var title_f24_52_25419="Heme negative red urine";
var content_f24_52_25419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of heme-negative red urine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deferoxamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron sorbitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrofurantoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenazopyridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenolphthalein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Food dyes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beets (in selected patients)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blackberries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food coloring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile pigments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homogentisic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphyrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tyrosinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urates",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25419=[""].join("\n");
var outline_f24_52_25419=null;
var title_f24_52_25420="Motor weakness with nerve root lesions";
var content_f24_52_25420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Motor weakness with nerve root lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nerve root level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Muscles involved",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        C5-C6",
"       </td>",
"       <td>",
"        Deltoid",
"       </td>",
"       <td>",
"        Shoulder abduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biceps",
"       </td>",
"       <td>",
"        Elbow flexion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        C6-C7",
"       </td>",
"       <td>",
"        Flexor carpi radialis",
"       </td>",
"       <td>",
"        Wrist flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triceps",
"       </td>",
"       <td>",
"        Elbow extension",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        C8-T1",
"       </td>",
"       <td>",
"        Abductor pollicis brevis",
"       </td>",
"       <td>",
"        Thumb abduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abductor digiti minimi",
"       </td>",
"       <td>",
"        Finger abduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensor indicis proprius",
"       </td>",
"       <td>",
"        Index finger extension",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        L2-L3-L4",
"       </td>",
"       <td>",
"        Iliopsoas (L1-L3)",
"       </td>",
"       <td>",
"        Hip flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quadriceps",
"       </td>",
"       <td>",
"        Knee extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adductor longus",
"       </td>",
"       <td>",
"        Hip adduction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        L5",
"       </td>",
"       <td>",
"        Tibialis anterior",
"       </td>",
"       <td>",
"        Foot dorsiflexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tibialis posterior",
"       </td>",
"       <td>",
"        Foot inversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peroneus longus",
"       </td>",
"       <td>",
"        Foot eversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensor digitorum brevis",
"       </td>",
"       <td>",
"        Toe extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gluteus medius",
"       </td>",
"       <td>",
"        Hip abduction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        S1",
"       </td>",
"       <td>",
"        Gastrocnemius",
"       </td>",
"       <td>",
"        Foot plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hamstrings",
"       </td>",
"       <td>",
"        Knee flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gluteus maximus",
"       </td>",
"       <td>",
"        Hip extension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Seward Rutkove and Andrew Tarulli.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25420=[""].join("\n");
var outline_f24_52_25420=null;
var title_f24_52_25421="Sample exchange system menu";
var content_f24_52_25421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample exchange system meal plan",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exchange pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample menu",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carbohydrate count (g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        8 am",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        3 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 English muffin",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 1/4 c strawberries",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 protein group",
"       </td>",
"       <td>",
"        1/4 c cottage cheese",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 fat group",
"       </td>",
"       <td>",
"        1 tsp margarine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total: 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        12 noon",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        4 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 slices of bread",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 orange",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 vegetable",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 c salad",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 oz skim milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 protein group",
"       </td>",
"       <td>",
"        3 oz chicken",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 fat group",
"       </td>",
"       <td>",
"        1 tbsp low fat mayo",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total: 57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        3 pm",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        1 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit or 1 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 apple or 6 crackers",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total: 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        6 pm",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        4 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 c potato",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/2 c fruit salad",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 vegetable",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 c salad",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 oz skim milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 protein group",
"       </td>",
"       <td>",
"        6 oz fish",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 fat group",
"       </td>",
"       <td>",
"        2 tbsp low fat salad dressing",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <strong>",
"         Total: 57",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        9 pm",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        1 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 crackers",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 protein",
"       </td>",
"       <td>",
"        2 tbsp peanut butter",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <strong>",
"         Total: 15",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25421=[""].join("\n");
var outline_f24_52_25421=null;
var title_f24_52_25422="Leaded gasoline";
var content_f24_52_25422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Marked reduction in consumption of tetraethyl lead following the phase-out of leaded gasoline in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    US Department of the Interior, Bureau of Mines, \"Lead,\" in Minerals Yearbook 1920-89 (Washington: GPO, 1921-90). No statistics for tetraethyl lead were published prior to 1941.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Warren, C. Brush with Death: A Social History of Lead Poisoning. The John Hopkins University Press, Baltimore 2000. p.32.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25422=[""].join("\n");
var outline_f24_52_25422=null;
var title_f24_52_25423="Cholesteatoma tympanic membrane";
var content_f24_52_25423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholesteatoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple white pearls on the lateral surface of the right tympanic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kim, SA, Haupert, MS. Clinical photograph: Congenital cholesteatoma of the tympanic membrane. Otolaryngol Head Neck Surg 2002; 127:359. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_52_25423=[""].join("\n");
var outline_f24_52_25423=null;
